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DUAL MECHANISM ANALGESIA-ENHANCING AGENTS 
By Shawquia Elithia Young, M.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2005 
Major Director: Malgorzata Dukat 
Associate Professor, Department of Medicinal Chemistry 
Co-Director: Richard A. Glennon 
Professor, Department of Medicinal Chemistry 
Currently, there is an increasing need for novel analgesics that are potent but lack 
undesired side effects. Recent studies have shown that both 5-HT3 receptors and a2B- 
adrenoceptors play a role in antinociception. MD-354, N-(3-chlorophenyl)guanidine, has a 
high-affinity both for 5-HT3 and a2B-adrenoceptors and could be viewed as the first 
example of a rather selective 5-HT3/a2B-adrenoceptor ligand. MD-354, inactive by itself, 
potentiates the antinociceptive effects of an inactive dose of clonidine in the mouse tail- 
flick assay. An attempt to determine the underlying mechanism of this potentiating effect 
was the purpose of the present investigation. The studies focused on an examination of: i) 
xvi 
MD-354 in the mouse hot-plate assay, ii) a more lipophilic analog of MD-354 in the tail- 
flick assay, iii) various analogs of MD-354 with different binding profiles in both mouse 
tail-flick and hot-plate assays. The present investigation suggests that both 5-HT3 and a2~- 
adrenoceptors are playing a role in the potentiation of clonidine analgesia by 
arylguanidines such as MD-354. Arylguanidines might represent a unique class of 
analgesia-enhancing agents with a dual (5-HT3/a2-adrenoceptor) mechanism of action. 
I. Introduction 
The development of an analgesic that is effective but free of serious side effects 
remains a major focus in the field of drug discovery. There are many drug classes that 
have analgesic properties and are being used to reduce all degrees of pain. Examples of 
these classes are nonsteroidal anti-inflammatory drugs (NSAIDs), local and general 
anesthetics, opiates, and m-adrenoceptor agonists.' These agents' analgesic effects can 
often be enhanced when used in combination with other analgesics or with one another. 
Some of these agents have become very useful in the treatment of severe pain for patients 
in post-surgery. Morphine and clonidine are popular analgesics that are currently being 
used for this type of 
Morphine was originally isolated in 1803 and was one of the first agents classified 
as an opiate.' Morphine binds at opioid receptors and more specifically, mu opioid 
receptors.4 It is a potent agent and is often referred to as a narcotic analgesic.' This means 
that morphine can induce sleep and/or a state of narcosis in addition to its analgesic 
effects.' Although morphine has been very successful in the treatment of severe pain, there 
are some limitations with its use. Some of the serious side effects of morphine are 
tolerance, physical and psychological dependence, respiratory depression, and 
c ~ n s t i ~ a t i o n . ~ - ~  
Clonidine is an agent currently being used in regional anesthesia for the 
management of acute post-operative pain, labor pain, or chronic pain.7 Clonidine binds 
both at a2-adrenoceptors and imidazoline receptors.8 It binds nonselectively at a2- 
adrenoceptors, which means that it binds with similar affinity at all of the a2-adrenoceptor 
subtypes (a2A, a 2 ~ ,  a2c). Evidence shows that the analgesic effects of clonidine are due to 
its partial agonist activity at a2-adrenoceptors.3 Similar to morphine, clonidine is a potent 
analgesic but also has its limitations. Some of the side effects associated with this agent 
are sedation, hypotension, and bradycardia.3'7 Due to its ability to lower blood pressure, 
clonidine is also being used to treat hyperten~ion.~ The sedative effects caused by 
clonidine also can be considered a desired effect, and its induced sedative effect is useful 
when clonidine is being used as an anesthetic. However, when it is being used as a post- 
operative analgesic, sedation can become a serious drawback. 
Due to the undesired side effects associated with both morphine and clonidine, the 
development of novel agents without these effects has become a major focus in the 
improvement of analgesics. Several novel pathways have proven to play some role in 
nociception. One example is the dopaminergic pathway. Dopamine receptors have been 
related both to pronociception and ant inoci~e~t ion .~  Specifically, Dz receptors are involved 
with inducing ant inoci~e~t ion .~  Therefore the use of D2 agonists for pain relief can be a 
possible novel pathway. Many of the classes in the serotonin receptor family also play a 
role in nociception. It has been implicated that the 5-HT3 receptor class plays a significant 
role in producing analgesia. However, there are currently available only a small number of 
selective 5-HT3 receptor agonists. Since clonidine is already a well-used analgesic, another 
3 
therapeutic approach might be to reduce the side effects caused by this agent (i.e., 
sedation). Evidence shows that the sedative and hypotensive effects of clonidine are due to 
the activation of the ~t~~-adrenoceptor  subtype.3 Recent studies have shown that the a 2 ~ -  
adrenoceptor subtype contributes to antinociception but is not involved in ~eda t ion .~  5-HT3 
and ~t~~-adrenoceptors have become potential pathways that could contribute to the 
development of novel classes of analgesics without the drawbacks of morphine and 
clonidine. In our laboratory, a novel series of arylguanidines has been developed and has 
been shown to bind at 5-HT3 and/or a2-adrenoceptors. This exciting development can 
possibly lead to a dual-mechanism analgesic agent. The purpose of the present study is to 
investigate the antinociceptive effects, and the mechanism of action, of the arylguanidines. 
11. Background 
A. Pain 
Due to the inconvenient side effects associated with current analgesic therapies, 
pain is usually inadequately treated in most patients. Pain can be defined as "an unpleasant 
sensory and emotional experience associated with actual or potential damage".I0 It consists 
of a mechanism that prevents any potential damage that can occur to the tissue.'' 
Therefore, any potential analgesic cannot compromise or prevent this protective 
mechanism from occurring which could lead to permanent damage. There are three types 
of pain: nociceptive, inflammatory, and neuropathic pain.1091' Nociceptive pain is the most 
common type of pain experienced in everyday life. It is referred to as a usual response to a 
brief noxious stimulus that induces little tissue Inflammatory pain is usually 
associated with trauma, infection, surgery, burns, or diseases that cause inflammation. 
Neuropathic pain is a painhl response that is induced by damage involving the peripheral 
or central nervous system and is usually associated with infection, tissue trauma, and 
autoimmune diseases.1° In some cases, one mechanism can produce pain and in others, 
different mechanisms can c o e ~ i s t . ' ~  
Pain can also be classified into different categories, e.g. acute, chronic, and cancer. 
Acute pain is defined as pain that is short with an identifiable cause and represents the 
largest class of pain being treated. It involves mild to moderately severe pain that is 
5 
usually managed by the NSAIDS.'"~"' The side effects that accompany the use of NSAIDs 
are gastrointestinal, renal, and liver toxicity. Opioids are also used when the NSAIDs fail 
to manage moderate to severe acute pain. As mentioned earlier, the opioid class has its 
own side effects that limit its use. Chronic pain is typically defined as pain that extends for 
a duration of time in which the cause is u n k n o ~ n . ' ~ , ' ~  Usually it is the common cause of 
major disability.'? Currently, there is no completely effective management or treatment for 
chronic pain. However, opioids have been used in an attempt to manage this type of pain 
as much as possible. Cancer pain is usually under-recognized or inadequately treated in 
12 
many cancer patients. It can be acute or chronic depending on the stage of the disease. 
The pain can come from various sources associated with cancer such as the tumor itself, 
chemotherapy, radiotherapy, or surgery.'0 
Pain can be associated with mechanical, chemical, and thermal stimuli. Mechanical 
stimulus can cause intense pain such as pinching of the skin, traumatic injury, or 
neuropathic  condition^.'^"^ Thermal stimuli involve the application of extreme 
temperatures to the peripheral tissues, e.g. heat or cold. Chemical stimuli involve 
application of acidic or basic chemicals to peripheral tissues.13 This latter type of stimulus 
is the slowest of the three in producing nociceptive responses, and the pain produced is 
inescapable.I3 After the noxious stimulus interacts with the peripheral tissues, the primary 
afferent nociceptive pathways become activated. Nociceptor C and A6 primary afferent 
fibers (PAFs) transduce the stimuli into electrical activity where the nociceptive 
information is then integrated in the dorsal horn located on the spinal cord."'14 These two 
types of PAFs both are nocisponsive, which respond to noxious chemical, thermal, and 
6 
mechanical stimuli.I4 The myelinated A6 fibers elicit the first phase of pain that is rapid 
and sharp;9714 whereas the unmyelinated C fibers induce the second phase of pain which is 
slower and PAFs can directly activate the projection neurons that can relay this 
information to the brain or indirectly activate them through the excitatory inter neuron^.^"^ 
The nociceptive information can also be transferred by the PAFs by stimulating the 
inhibitory interneurons. These interneurons can also interact with projection neurons, 
excitatory interneurons, and the PAFs' terminals.9714 This process plays an important role 
in the operation of the descending pathways of nociception. The descending pathways are 
comprised of two mechanisms: descending inhibition and descending facilitation. 
Descending inhibition is the primary mechanism that produces antinociception. This 
response is produced by reducing the release of neurotransmitters from the PAFs' 
terminals that aid in transmitting the pronociceptive information. 9,1 1,14 The projection 
neurons are inhibited by inhibiting the excitatory interneurons and simultaneously 
stimulating the inhibitory interneurons.I4 This activity occurs postsynaptically to the 
terminals of the P A F S . ~ ? ' ~  Descending facilitation promotes pronociception. This pathway 
elicits stimulation of the excitatory interneurons and projection neurons which leads to an 
increase in nociceptive transmission. 
The brainstem and other cerebral structures are the origin of the descending 
pathways. 9,l 1,14,15 Many supraspinal regions play an essential role in the modulation of 
nociceptive information. After the message is integrated in the dorsal horn, it is conveyed 
to the brain through the spinothalamic and spinobrachial pathways." From the former 
pathway, the activity is transferred through the thalamus to the somatosensory cortex."~14 
7 
The parabrachial region is connected to other supraspinal sites such as the hippocampus, 
amygdala, and other regions which are involved in the nociceptive response. 9,l 1,14 This 
message is then integrated in the periaqueductal gray which plays a major role in 
promoting and inhibiting pronociception. ' 
Briefly mentioned earlier, the release of neurotransmitters is involved in pain 
transmission. The most investigated neurotransmitters involved in descending pathways 
are norepinephrine and serotonin (~-HT)." These two neurotransmitters can modulate the 
flow of nociceptive information to the brain via its activity in the dorsal horn. 
Norepinephrine is a part of the descending noradrenergic pathway and it interacts with 
multiple classes of adrenoceptors (P, a l ,  a*). Serotonin is involved in the descending 
serotoninergic pathway and this neurotransmitter interacts with the 5-HT receptor 
superfamily (5-HT1-5-HT7). 
B. 5-HT3 Receptors 
1. Classification 
Serotonin (5-hydroxytryptamine, 5-HT; 1) is a neurotransmitter that binds at 
several 5-HT receptor populations and is involved with a variety of physiological effects in 
the body. Some of these effects include vasoconstriction, vasodilation, body temperature 
regulation, appetite, mood, platelet aggregation, sleep, and hormonal regulation.I6 These 
different physiological effects are due to the ability of 5-HT to bind at a variety of 5-HT 
receptors. 5-HT receptors are classified as belonging to seven major families (5-HT1-5- 
HT7). 
All of the 5-HT receptors are G-protein coupled receptors, except 5-HT3 receptors 
which are ligand-gated ion channel (LGIC) receptors. There are major differences in 
receptor function between G-protein coupled receptors and LGIC receptors. A G-protein 
coupled receptor's functions are mediated via second messenger systems. This mechanism 
is a multi-step receptor-effector cascade that elicits relatively slow cellular responses. 
These receptors transmit this signal by activating a guanine nucleotide binding protein (G- 
protein). G-Proteins consist of three subunits: a ,  P, y, in which the a subunit modulates 
the activation of the G-protein. The ligand binds to the G-protein coupled receptor and 
causes the G-protein to bind to a target enzyme. This enzyme then triggers a second 
messenger that results in the cellular response. In the 5-HT family, the second messenger 
systems that are involved are stimulation or inhibition of adenyl cyclase and stimulation of 
phospholipase c . ' ~  
An- 
- 
Figure 1. G-Protein coupled receptor'' 
5-HT3 receptors are a member of the cys-loop superfamily which includes the 
nicotinic acetylcholine (nACh) receptors, GABA*, and glycine receptors. A LGIC 
receptor's major function is to modulate the rapid transmission of synaptic nerve impulses 
which are caused by the binding of neurotransmitters to the specific receptor. This process 
results in the opening of an ion-selective pore.'6 In the case of 5-HT3 receptors, 5-HT binds 
to the receptor and allows specific cations, such as ~ a ' ,  IS', and ca2' to move through the 
lipid membrane. Activation of these receptors produces various effects including 
membrane depolarization, increase in intracellular ca2', and the modulation of 
neurotransmitter release.I8 
2. Structure 
The receptors in the cys-loop family typically are similar in structure. The most 
extensively studied receptor is the nACh receptor. These pentameric receptors have five 
homologous subunits (Figure 2) that consist of four transmembrane spanning domains 
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(TMl-TM4) (Figure 3), an intracellular loop between TM3 and TM4, and a large 
extracellular N-terminal It is suggested that the N-terminal domain is where 
the ligand-binding domain is located.16 In this domain, there are 2 cysteine residues that 
are linked by a disulfide bond. 5-HT3 receptors share about 20-30% amino acid sequence 
identity with the nACh receptors.I6 since the crystal structure of the ACh binding protein 
(AChBP) was recently determined, this facilitates the study of the 5-HT3 ligand binding 
domain due to their structural similarities. 
OOH 
Figure 2. Quaternary structure of a LGIC receptor, and Figure 3. Topology of a LGIC 
the location of the TM2 lining the pore receptor subunit 
5-HT3 receptors have been classified into three subunits: 5-HT3~,  5-HT3~,  and 5- 
H T , ~ . ' ~  However, only the 5-HT3* and 5-HT3B subunits have been cloned.I6 The 5-HT3* 
subunit has been cloned from a mouse neuroblastoma/Chinese hamster embryonic brain 
cell hybrid, rat sympathetic neurons, human brain, guinea pig small intestine and ferret 
colon.I6 The 5 - H T 3 ~  subunit has been cloned from human fetal kidney, human small 
intestine, and mouse and rat brain.I6 The 5-HT3A subunit is expressed in heterologous 
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expression systems and has structural similarities with the other receptors in the cys-loop 
s ~ ~ e r f a m i l ~ . ~ ~ ~ ~ ~  The protein sequence similarity between 5 - H T 3 ~  and the a-subunits of 
the other members is 22-30%.16 It has been suggested that the 5-HT3 receptor is a common 
ancestor of all LGIC receptors because it is relatively similar to a7  nACh receptor 
subunits.I6 The 5 - H T 3 ~  subunit consists of 487 amino acids and three potential N- 
glycosylation sequences that are located in the extracellular region.I6 These N- 
glycosylation sites could potentially be involved in the assembly of the 5-HT3 receptor.I6 
5 - H T 3 ~  receptor is a protein that can form fully functional homomeric complexes. This 
subunit plays a pivotal role in the pharmacological effects elicited by 5-HT3 receptors. 
Recently, three variant forms of the 5-HT3* subunit have been identified in humans.22 
These variants include normal, short, and long isoforms. The short variant is a polypeptide 
unable to form functional homomeric ion channels, and they are coexpressed with the 
normal 5 - H T 3 ~  receptor. It consists of 238 amino acids and forms only a single 
transmembrane domain. It has a very short C-terminus but encodes the ligand binding 
domain in the extracellular ~ - t e r r n i n u s . ~ ~  The long variant of 5 - H T 3 ~  consists of 510 
amino acids which is 23 amino acids longer than the normal variant. It also does not form 
functional homomeric ion channels.22 These additional amino acids are inserted in the 
extracellular loop between the TM2 and TM3 domain.22 
The 5-HT3B subunit cannot form homomeric complexes but can form heteromeric 
complexes with the 5-HT3A subunit. This subunit has -45% sequence identity with its 5- 
H T 3 ~  h o m ~ l o ~ . ' ~  The 5-HT3R subunit has no function by itself, but elicits its function when 
it is coexpressed with the 5 -HT3~ subunit. This receptor subunit has 441 amino acids and 
also has extracellular N-glycosylation sites as seen in the 5 - H T 3 ~  subunit. The 5-HT3B 
subunit does not possess any of the structural features needed to induce the conductance 
seen in the other LGIC receptors, and that causes its inability to form functional ion 
channels." When this subunit forms a heteromeric complex with the 5-HT3* subunit, there 
are no relatively significant changes in the normal pharmacological function of the 5-HT3 
receptor. The only changes in function that the heteromeric complex shows are a larger 
single-channel conductance and a decrease in ca2+ permeability.20 The 5-HT3c subunit was 
just recently patented and its function is still unclear.'6123 This receptor shows -39% 
sequence identity to its 5 - H T 3 ~  h ~ m o l o ~ . ' ~  It has been suggested that the 5-HT3c subunit 
contributes to the regulation of the 5-HT3 receptor's responses. 23 
3. Pharmacology 
Evidence shows that 5-HT3 receptors are distributed throughout the CNS among 
different species. In rats, these receptors are expressed in the forebrain, brainstem, and the 
spinal cord. Some of these regions include the solitary tract nucleus, nucleus of spinal tract 
of trigeminal nerve, dorsal horn of the spinal cord, and hippocampus.24~25 In mice, 5-HT3 
receptors are distributed in similar regions of the spinal cord and forebrain as in the rats. 
They are expressed in the hippocampus, dorsal tegrnental nucleus, trochlear nerve nucleus, 
facial nerve nucleus, dorsal root ganglia, olfactory and somatosensory regions, and 
throughout the cortical regions and limbic system.26 In humans, the majority of 5-HT3 
receptors in the CNS are the 5-HT3A subunit." These receptors are also distributed in the 
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forebrain, hindbrain, medulla oblongata, spinal cord and, to a lesser extent, in the nucleus 
accumbens, and striatum and substantia nigra.20 
5-HT3 ligands have become important tools in studying the 5-HT3 receptor. For 
instance, 5-HT3 antagonists are being used to determine thk distribution of these receptors 
throughout the body. Various assays have been developed in order to differentiate between 
5-HT3 agonists and antagonists. One of the first in vivo assays that was used is the von 
Bezold-Jarisch reflex. In this assay, the cardiovascular system is the primary site of 
activity and the reflex causes a triad of responses that are apnea, bradycardia, and 
hypotension.27 When a 5-HT3 agonist is administered it produces the von Bezold-Jarisch 
reflex and mainly causes bradycardia. If an agent blocks this response in the presence of 
the 5-HT3 agonist, then it can be referred to as an antagonist in this hnctional assay. This 
in vivo assay is well known and is still currently being used to investigate 5-HT3 agonists 
and antagonists. Another in vivo assay is the ferret and shrew emesis assay.28 In this assay, 
cisplatin, a vomiting-inducing agent, is administered to the animal to cause emesis.28 A 5- 
HT3 antagonist will prevent this emetic response from occurring and a 5-HT3 agonist 
induces emesis. Stimulation of 5-HT3 receptors has been shown to also produce 
contractions in the gastrointestinal tract. An important in vitro functional assay that 
focuses on this response is the contraction of isolated guinea pig ileum. In this assay, 
administration of 5-HT3 agonists produces contractions. If an agent can block these 
contractions it is referred to as an antagonist. In some cases, a 5-HT3 ligand can show 
agonist activity in one functional assay and antagonist activity in another assay. The 
14 
determination of these ligands has played a pivotal role in fully understanding 5-HT3 
receptors and their many functions. 
4. Ligands and Structure-Activity Relationships (SAR) 
a) Agonists 
Over the years a variety of drug classes have been shown to bind selectively to 5- 
HT3 receptors. Both agonist and antagonists have been studied and some antagonists are 
currently being used clinically in the treatment of a variety of disorders. To date, there are 
few available 5-HT3 agonists to study their pharmacological effects. The first class of 
agonists found to bind to these receptors is the tryptamines. 5-HT (I), a member of this 
class, binds to 5-HT3 receptors nonselectively and with moderate affinity (Ki =1,000 n ~ ) . ~ ~  
2-Methyl 5-HT (2) was found to display more selectivity for 5-HT3 receptors than 5-HT 
but binds with slightly lower affinity (Ki ~ 1 , 3 5 0  n ~ ) . ~ ~  2-Methyl 5-HT is one of the few 
currently available 5-HT3 agonists being used. Recent investigations have shown, 
however, that 2 binds at 5-HT6 receptors (Ki = 45 nM) with higher affinity than it displays 
for 5-HT3 receptors. 29 
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Different analogs of 5-HT were studied and it was found that trimethylation of the terminal 
amine (5-HTQ, 3) resulted in a highly selective 5-HT3 agonist (K; = 75 n ~ ) . ~ '  This 
quaternary amine binds with a ten times higher affinity than 5-HT (I), but has difficulty in 
penetrating the blood-brain barrier (BBB) and is of limited k e  for in vivo studies." 
The arylbiguanides represent another class of 5-HT3 agonists that are 
nontryptamines and selective for this receptor. Phenylbiguanide (PBG, 4) was the first 
agent of this class to be developed and it displayed moderate affinity (K; =1,200 nM) 
comparable to 5-HT. m-Chlorophenylbiguanide (m-CPBG, 5; Ki = 17 nM) was found to be 
a higher affinity agent than P B G . ~ ~  Structure-activity relationship (SAR) studies were 
conducted by Dukat et and the major focus was the modification of the aryl 
substituents and the biguanide chain. In aryl substitution, analogs with different functional 
groups at various positions on the phenyl ring were studied (Table 1).25 The primary goal 
of this study was to examine the electronic and lipophilic character of these substituents 
and their effect on affinity.23 Addition of a chloro group at the 2- or Cposition resulted in 
higher affinity than PBG but in lower affinity than m-CPBG (6, 7, Ki = 62 and 200 nM, 
respectively). Replacing the 3-chloro group with a nitro (8) or trifluoromethyl (17) group, 
stronger electron-withdrawing groups, resulted in a decrease in affinity (Ki = 220 nM and 
700 nM, r e ~ ~ e c t i v e l ~ ) . ~ ~ . ~ '  Also, replacing the chloro group with a methyl group, an 
equally lipophilic and more electron-donating group, resulted in decreased affinity (9, Ki 
= 780 nM). Replacement by a 4-methyl group abolishes affinity (10) but adding a chloro 
group at the 3-postion to this derivative enhances affinity (11, Ki = 225 nM). Addition of a 
methoxy group to the 2-position and a chloro group in the 5-position also enhances affinity 
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when compared to PBG (12, Ki =I26 nM). The 2-napthyl derivative 13 (Ki = 12 nM) binds 
with high affinity that is similar to m-CPBG. From this study it was found that the 3- 
chloro substituent was optimal for binding. In separate studies, it was found that 
incorporating chloro substituents at the 4- andlor 5-posi'tions resulted in even higher- 
affinity agents (14, 15, 16, Ki = 12, 1.8, and 2.7 nM, respectively).30 
Table 1. Observed Binding Affinities of Arylbiguanides for 5-HT3 ~ e c e p t o r s . ~ ~  
4-12 and 14-17 13 
17 
Next, the biguanide chain was modified. Dimethylation of the terminal amine 
resulted in abolished affinity (18; Ki > 10,000 n ~ ) . ~ '  Various derivatives were studied and 
it was shown that any further modification (with one exception) of the biguanide chain also 
abolished affinity.30 However, the ~-(2-~hen~leth~l)~uanidine 19, (Ki = 40 nM) displayed 
high affinity.30 More importantly, it was found that the entire biguanide chain was not 
necessary for binding and could be shortened; this resulted in the arylguanidines.30 
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This novel class of compounds, the arylguanidines, was found to bind with 
affinities comparable to the arylbiguanide~.~~ Between the two classes parallel structural 
changes led to parallel shifts in affinity.31 SAR studies were conducted and both aryl 
substitution and the guanidine moiety were examined (Table 2). As with the 
arylbiguanides, a chloro group at the 3-position is optimal. m-Chlorophenylguanidine 
(MD-354, 21) binds with high affinity and was the first agent developed in this class (Ki = 
35 n ~ ) . ~ '  Also, as with the arylbiguanides, high affinity was not retained when the chloro 
group was replaced with a trifluoromethyl group (24, Ki = 5700 nM). Addition of chloro 
groups at the 4- andlor 5-positions led to higher affinity agents as in the arylbiguanide 
series (27, 28, 29, Ki = 3.1, 5.0, and 0.7 nM, respectively). Conformationally constrained 
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analogs of MD-354 were also examined as possible ligands.32 Benzimidazole 30 and 
quinazoline 31 were developed and it was found that only the quinazoline displayed high 
affinity (K; = 725 and 34 nM, respectively). Although some of the arylguanidines bind at 5- 
HT3 receptors with high affinity, they might have difficulty penetrating the BBB. 
Theoretically, an agent should possess a Log P value that falls in the 1.5 to 2.5 range in 
order to penetrate the BBB.'~ MD-354 (21) has a Log P value of -0.64 which suggests that 
this agent will have difficulty penetrating the B B B . ~ ~  This could limit the use of 
arylguanidines in behavioral studies, and their potential clinical use for treating central 
disorders. 
Table 2. Observed Binding Affinities of Arylguanidines at 5-HT3 ~ e c e ~ t o r s . ~ ~ " ~  
b) Antagonists 
When compared with the 5-HT3 agonists, there are definitely more available 
antagonists for research and on the 5-HT3 antagonists are currently being used 
clinically in the treatment of irritable bowl syndrome and as antiemetics. These 
antagonists include zacopride (32), tropisetron (33), ondansetron (34), and granisetron 
(35), just to mention a few representative examples.34 Zacopride (32) is an extremely 
potent blocking agent that binds at 5-HT3 receptors (Ki= 0.1-1.9 nM), but it also acts as an 
agonist at 5-HT4 receptors (Ki= 1.1 n ~ ) . ~ ~  Tropisetron (33) (formerly known as ICS 205- 
930) was one of the first clinically used antiemetics among the 5-HT3 antagonists. It acts as 
an antagonist at both 5-HT3 and 5-HT4 receptors (Ki= 0.4-3.2 and 930 nM, respectively).35 
Both ondansetron (34) and granisetron (35) bind selectively at 5-HT3 receptors with high 
affinity (Ki= 0.8-13 and 0.3-4.2 nM, respectively).35 Radiolabeled versions of these agents 
have also been used as radioligands in binding studies, and were involved in determining 
the distribution of 5-HT3 receptors in the CNS." These agents also are useful in 
evaluating the functional roles of these receptors. 
f i ~ ~  
Zacopride (32) Tropisetron (33) 
Ondansetron (34) Granisetron (35) 
5-HT3 receptors have become major targets in the development of novel agents for 
the treatment of a variety of disorders due to their general lack of side effects.34 
Ondansetron (34) is being used clinically to relieve nausea and vomiting associated with 
cancer chemotherapy, radiation, and ane~thes ia .~ ' ,~~ 5-HT3 antagonists block emesis by 
producing antagonism of the receptors located at central sites.36 Ondansetron (34) is 
highly effective but does not completely eliminate nausea and vomiting.34 When compared 
with previous antiemetics (i.e., scopolan~ine), the 5-HT3 antagonists do not cause any 
sedation.34 5-HT3 receptors also play a role in anxiety, and it is suggested that 5-HT3 
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antagonists could be used as potential a r~x io ly t i c s .~~ '~~  In clinical studies, however, it was 
shown that the 5-HT3 antagonist granisetron (35) was not as effective as the 
benzodiazepines as an anxiolytic. However, these antagonists did not produce any of the 
side effects, such as sedation and rebound anxiety following chronic treatment, seen with 
the b e n z ~ d i a z e ~ i n e s . ~ ~  Another area in which 5-HT3 receptors are involved is gut motility. 
The stimulation of these receptors could cause diarrhea, which is commonly referred to as 
intestinal hyperrnotility.36 This is usually associated with irritable bowel syndrome. 5-HT3 
antagonists could potentially be used in the treatment of diarrhea. On the other hand, 5- 
HT3 agonists could also be used in the treatment of constipation.23 Since it is suggested 
that stimulation of 5-HT3 receptors increases intestinal motility in this disorder, it could be 
beneficial to use a 5-HT3 agonist which is effective and does not induce emesis and 
diarrhea.23 
As discussed earlier, 5-HT3 receptors have been implicated as playing a role in 
nociception. This is summarized in Table 3; earlier radioligand binding studies showed that 
5-HT3 receptors are located on sensory nerve endings in the periphery, on the soma and 
axon membranes of sensory neurons, and on primary afferent terminals in the spinal 
~ o r d . ~ ~ , ' ~  It was also shown that 5-HT3 receptors located on peripheral sensory neurons are 
involved in inflammatory, but not mechanical or thermal, pain in animal models.36 For 
example, Giordano et showed that the subcutaneously (s.c.) administered 5-HT3 
receptor antagonist tropisetron (33) did not produce analgesia in thermal and mechanical 
nociceptive tests. However, tropisetron produced analgesia in the formalin test, a chemical 
nociceptive test.40 In this test, formalin induces inflammatory pain which is blocked by 
tropisetron. Also in this study, both central and peripheral 5-HT3 receptors were examined. 
When tropisetron was injected by intracerebroventricular (i.c.v.) administration, it was 
found to be ineffective in producing analgesia in acute thermal, mechanical, and chemical 
pain tests.40 The lack of analgesic activity of 5-HT3 receptor antagonists in thermal and 
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mechanical pain tests supports the hypothesis that 5-HT3 receptors do not mediate the 
transmission of nociceptive signals.40 However, the antinociceptive effect produced by 5- 
HT3 antagonists in the formalin-induced pain test further suggests that 5-HT3 receptors 
induce a response to inflammatory pain.40 These results also suggest that supraspinal 5- 
HT3 receptors might not be involved in mediating this response since these antagonists 
were administered (i.c.v.) directly into the brain and did not produce a n t i n o c i ~ e ~ t i o n . ~ ~  In 
a separate study, the 5-HT3 receptor agonist 2-methyl 5-HT (2) was also analyzed in the 
formalin-induced test.41 2-Methyl 5-HT was administered it., and found to produce an 
antinociceptive response.4' This antinociceptive response was reduced by i.t. administered 
MDL-72222, a potent 5-HT3 receptor antagonist.41 According to these results, it further 
suggests that spinal 5-HT3 receptors induce antinociceptive responses to inflammatory 
pain. This analgesic activity could also be reduced by ketanserin (5-HT2 antagonist), 
naloxone (opioid antagonist), and bicuculline (GABAA antagonist).41 Because this 5-HT3 
receptor-mediated antinociception could be attenuated by various other antagonists, this 
suggests that the 5-HT3 descending inhibitory system is interacting with 5-HT2, GABAA, 
and opioid receptors. When 2-methyl 5-HT (2) was administered i.c.v., it did not produce 
any antinociceptive activity.4' This also supports the idea that supraspinal 5-HT3 receptors 
do not mediate nociceptive responses to inflammation. This receptor has been shown to 
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mediate a component of the nociceptive response to subacute and chronic inflammation 
caused by 5-HT and other noxious agents, however the initial phase of inflammation and 
acute pain does not seem to be reliant on the 5-HT3 receptor.39 2-Methyl 5-HT and 5-HT 
were also analyzed in the writhing test.39 This test was used to study visceral 5-HT3 
receptors' role in modulating nociceptive responses. In this study intraperitoneally (i.p.) 
administered 5-HT produced a dose-dependent nociceptive writhing response that was 
blocked by tropisetron (33) (1 mgikg, i.p.).39 However, 2-methyl 5-HT (2) did not produce 
any nociceptive responses or writhing when administered alone. But, when 2-methyl 5-HT 
was administered following a low dose of 5-HT, it showed enhancement in the 
antinociceptive activity of ~ - H T . ' ~  These results suggest that visceral 5-HT3 receptors 
could play a role in mediating inflammatory pain, but it seems to be dependent on other 
mechanisms to elicit its activity. This idea is demonstrated when 2-methyl 5-HT alone did 
not produce a nociceptive writhing response. Another possible explanation could be that 
since tropisetron is a 5-HT3 and 5-HT4 receptor antagonist, this specific dose could be 
interacting with 5-HT4 receptors which might be involved in this nociceptive activity. 
5-HT3 receptors were also shown to have a possible role in spinal nociception. This 
hypothesis has been studied via thermal pain tests in rodents. In a study by Glaum et 
it was shown that intrathecally (i.t.) administered 5-HT produced antinociceptive activity 
in the hot-plate test. This activity was attenuated by i.t. administered tropisetron (33) (0.01 
This study further supports the concept that 5-HT3 receptors mediate spinal 
analgesia. As mentioned earlier, various 5-HT3 receptor antagonists were analyzed in the 
hot water bath test in rats for possible antinociceptive activity.40 These antagonists did not 
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Table 3. Summary of 5-HT3 Ligand Activity in Various Animal Nociceptive Tests. 
Model 
Inflammatory 
pain 
Formalin test 
Writhing test 
Hot platel 
Hot water 
bath 
Tail flick 
Mechanical 
Agents 
Tropisetron 
MDL-72222 
Ondansetron 
2-Methyl 5-HT 
Tropisetron 
MDL-72222 
Ondansetron 
PBG 
Tropisetron 
Zacopride 
2-Methyl 5-HT 
PBG 
Tropisetron 
MDL-72222 
Ondansetron 
2-Methyl 5-HT 
mCPBG 
Agonist/ 
Antagonist S~ec ies  
Antagonist rats 
Antagonist rats 
Antagonist rats 
Agonist rats 
rats 
mice 
Antagonist rats 
Antagonist rats 
Antagonist rats 
Agonist rats 
Agonist rats 
Antagonist rats 
rats 
rats 
Antagonist rats 
Antagonist rats 
Agonist rats 
Agonist rats 
Antagonist rats 
Antagonist rats 
Antagonist rats 
Agonist rats 
rats 
Agonist rats 
Route of 
Admin. 
S.C. 
i.c.v. 
i.t. ' 
i.t. 
i.c.v. 
i.p. 
S.C. 
i.c.v. 
i.t. 
i.t. 
i.c.v 
i.t. 
S.C. 
i.c.v. 
i.t. 
i.t. 
i.t. 
i.t. 
i.t. 
S.C. 
i.c.v. 
i.t. 
i.c.v. 
i.t. 
i.t. 
Analgesic Activity 
Yes 
no 
no 
yesiblocked by 
5-HT3, 5-HT2, 
opioid,GABA 
antagonists 
no 
produces no 
nociceptive 
responses alone 
no 
no 
noiblocks 
analgesic 
effect of 5-HT 
yes/ reduced by 
5-HT3, 5-HT2, 
opioid, and 
GABA antagonists 
no 
Yes 
no 
no 
nohlocks i.c.v. 
morphine-induced 
analgesia 
nohlocks i.t. 
2-Methyl 5HT 
no 
yes/ blocked by 
5-HT3, GABA, a2 
and a-adrenoceptor 
antagonists 
no 
Ref. 
40 
40 
40 
41 
4 1 
3 9 
40 
40 
40,42 
4 1 
41 
43 
40 
40 
40,46 
40,42 
40 
42-44 
43 
4.0 
40 
40 
48 
48 
yes/ blocked by 5-HT3 49 
antagonists 
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produce any antinociceptive activity when administered subcutaneously (s.c.) or via the 
i.c.v. route.40 5-HT produces analgesic effects through influence on the CNS, and these 
effects can be mimicked by 2-methyl 5-HT (2).36)39 TO further characterize the role of 5- 
HT3 receptors in spinal analgesia, 2-methyl 5-HT was studied in the hot-plate test. 
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Giordano et showed that i.t. administered 2-methyl 5-HT produces antinociception in 
rats. This activity was reduced by 5-HT3, 5-HT2, opioid, and GABAA This 
study also showed the involvement of other systems with 5-HT3 receptors in mediating 
spinal analgesia. However, i.c.v. administered 2-methyl 5-HT did not produce 
ant ino~ice~t ion .~ '  These results suggest that supraspinal 5-HT3 receptors also might not 
mediate spinal analgesia. Another study showed that i.t. administered PBG (4), a 5-HT3 
agonist, produced analgesic activity.43 5-HT3 receptor ligands have also been analyzed in a 
second thermal test, the tail-flick test. This behavioral test focused on analgesic activity 
that was elicited by spinal 5-HT3 receptors. In a study by Glaum et both i.t. 
administered 5-HT and 2-methyl 5-HT produced antinociceptive activity that could be 
blocked by i.t. administered MDL-72222 and tropisetron (33). This study further supports 
the concept that 5-HT3 receptors mediate spinal analgesia. In a separate study, i t .  
administered 2-methyl 5-HT produced antinociception in mice that was also blocked by 5- 
HT3 and GABAA antagonists.44 The antinociceptive activity was only partially blocked by 
phalcofen (GABAB antagonist).44 In earlier studies, it was suggested that 5-HT3 receptors 
could mediate the release of GABA which elicits the antinociceptive activity.44 These 
results support this idea since both GABAA and GABAB antagonists can block the 
antinociceptive activity produced by 2-methyl ~ - H T . ~ ~  
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Noradrenergic receptors also play a role in mediating 5-HT-mediated 
antino~ice~tion." It was previously shown that i.t. administered norepinephrine and 5-HT 
produce a synergistic effect." Sawynok et showed that both 5-HT and 2-methyl 5- 
HT's antinociceptive activity could be reduced by phentolamine (nonselective a-AR 
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antagonist) and yohimbine (a2-AR antagonist). PBG (4) was also analyzed in the tail-flick 
test for possible antinociceptive activity. When administered it . ,  unlike 2-methyl 5-HT (2), 
PBG did not produce a n t i n o ~ i c e ~ t i o n . ~ ~  The difference in activity with 2-methyl 5-HT and 
PBG suggests that 5-HT3 receptors do not directly mediate spinal analgesia. 2-Methyl 5- 
HT could mediate the release of 5-HT, which then activates the 5-HT3 receptors. Another 
possibility could be that 2-methyl 5-HT is inducing antinociception via another serotonin 
receptor subtype. The latter possibility is less likely because analgesic activity produced by 
2-methyl 5-HT can be blocked by MDL-72222 which is selective for 5-HT3 receptors. 
Since it has been implicated that 5-HT mediates morphine-induced antinociception, a 
specific role for 5-HT3 receptors has been studied.46 It has been shown that i.t. 
administered morphine produces antinociception that can be blocked by t r ~ ~ i s e t r o n . ~ ~  I  a 
later study, i.t. administered tropisetron (33) also blocked i.c.v. administered morphine- 
induced antinociceptive activity.47 It is apparent that 5-HT3 receptors participate in a more 
complex system that mediates antinociception which involves a variety of receptor 
families. Figure 4 illustrates the overlapping of the different receptors and their possible 
roles in mediating analgesia.9 
DESCENDING INHIB1716N 
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DESCENDING FAC1LITAIIOU 
Figure 4. Schematic diagram of 5-HT serotonergic system modulating n o c i ~ e ~ t i o n . ~  This figure is 
used to show the involvement of the serotonergic system with other neurotransmitters. 
Mechanical nociceptive tests have been used to study possible involvement of 5- 
HT3 receptors in modulating an antinociceptive response to mechanical noxious stimuli in 
rodents. In a mechanical test, nociceptive responses are elicited by applying an increasing 
pressure to the paw or dorsal side of the distal tail of a rodent until a squeak or withdrawal 
response is As seen in certain other nociceptive tests, 5-HT3 receptors do not 
seem to be conclusively involved in antino~ice~tion.~' 2-Methyl 5-HT (2), administered i.t. 
and i.c.v., was studied and did not produce an antinociceptive response in the paw pressure 
test.48 In another study, mCPBG (5) and 5-HT were also analyzed in the paw pressure 
test.49 Both i.t. administered 5-HT and mCPBG produced a dose-dependent antinociceptive 
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response which was blocked by tropisetron and g a n i ~ e t r o n . ~ ~  5-HT produced higher 
antinociceptive effects than mCPBG, an agent which is more selective for 5-HT3 receptors 
than ~ - H T . ~ ~  This suggests that 5-HT3 receptors might be partially involved in producing 
an antinociceptive response to a mechanical stimulus.49 In the paw pressure test, two 5-HT3 
agonists, 2-methyl 5-HT (2) and mCPBG, showed different activities. Since mCPBG 
binds with higher affinity at 5-HT3 receptors, the findings suggest that the mechanism 
involved in the 5-HT-induced antinociception could be direct activation of 5-HT3 
receptors. This activation could lead to the partial antinociceptive response seen by 
mCPBG. It has also been shown that mCPBG is involved with the dopaminergic pathway 
and causes the release of d ~ ~ a n i i n e . ~ ~  This could also play a role in the partial 
antinociceptive actions of mCPBG since dopamine has been implicated in 
a n t i n o c i ~ e ~ t i o n . ~ ' ~ ~  Currently, results from animal studies that deal with the actual role of 
5-HT3 receptors in modulating nociception are controversial. Although there is substantial 
evidence to suggest that 5-HT3 receptors could mediate spinal analgesia, the mechanism of 
this activity is still unclear. Thus, additional studies are required before it can be concluded 
that 5-HT3 receptor agonists may or may not be useful in the treatment of acute pain. 
Many clinical studies have been conducted to determine the possible clinical utility 
of 5-HT3 receptor antagonists in the treatment of acute pain. Tropisetron (33) was one of 
the first selective 5-HT3 receptor antagonists to be used as a potential treatment of 
rheumatism, a condition characterized by inflammation or pain in muscles, joints, or 
fibrous t i~sue .~ '  Ferber et a1.52 showed that tropisetron was effective compared with 
placebo in reducing pain in patients with fibromyalgia in a double-blind study. The most 
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frequent complaints reported were constipation and heada~he.~ '  Muller et ~ 1 . ~ ~  reported 
that only up to 50% of patients with fibromyalgia actually responded to tropisetron with a 
reduction of pain. It was also hypothesized that 5-HT plays a key role in producing pain 
during an acute migraine attack.38 In an open pilot study, 5 out of 6 patients experienced a 
rapid relief of pain when treated with granisetron ( 3 ~ ) . ~ ~  In further studies, other 5-HT3 
receptor antagonists (i.e., ondansetron (34) and tropisetron (33)) did not consistently 
relieve the pain caused by a migraine attack.38 Stratz and ~ u l l e r ~ ~  showed that tropisetron 
was effective in the local treatment of rheumatoid arthritis, tendinopathies, peri- 
arthropathies, and myofasical pain syndrome. Overall these studies have shown that 5-HT3 
receptor antagonists can be useful in situations linked to inflammatory stimuli. 
It has been shown that 5-HT3 receptors might be involved in the modulation of 
nociception. The 5-HT3 receptor agonist %-methyl 5-HT showed analgesic activity in the 
inflammatory and thermal but not mechanical tests, whereas another 5-HT3 receptor 
agonist, PBG, did not produce analgesia. However, the more selective 5-HT3 receptor 
agonist mCPBG produced analgesic activity in the mechanical test. The 5-HT3 receptor 
antagonists only produced analgesic activity in the formalin-induced inflammatory test 
when administered via the S.C. route. From these results, demonstrating a role for 5-HT3 
receptors in mediating nociception has been quite difficult. Inconclusive findings with 5- 
HT3 receptor agonists could be related to their non-selectivity, low-affinity, andlor inability 
to penetrate the blood-brain barrier; thus, there is a definite need for the development of 
potent, centrally acting 5-HT3 agonists that have the ability to penetrate the blood-brain 
barrier. This controversy could also be due to factors dealing with the nociceptive tests 
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that were used. Other factors include route of administration, species, and 5-HT3 ligand 
used. Additional studies with more lipophilic 5-HT3 receptor agonists would certainly 
allow a clearer understanding of the involvement of 5-HT3 receptors in pain. 
I .  Classification 
The adrenoceptors, a receptor family that has been extensively studied over the 
years, are membrane receptors that belong to the superfamily of G-protein coupled 
receptors (GPCRs). They bind the endogenous catecholamines, norepinephrine (36) and 
epinephrine (37), which elicit a variety of physiological effects in both the central and 
peripheral nervous systems.55 Some of these effects include control of blood pressure and 
blood flow, neuronal modulation, digestion, respiration, reproduction, pupil dilation and 
contraction, and energetic rne tab~ l i sm.~~  Norepinephrine is released from the 
noradrenergic postganglionic nerve terminals, and both norepinephrine and epinephrine are 
secreted in the adrenal medulla.55 
Norepinephrine (36) Epinephrine (37) 
The adrenoceptors are divided into two broad categories, a -  and ~ - a d r e n o c e ~ t o r s . ~ ~  
a-Adrenoceptors can be further divided into a , -  and a2-adrenoceptors.56 The a and P 
adrenoceptors were initially classified according to the rank order of potency of a series of 
adrenoceptor agonists.57 For the a-adrenoceptors, epinephrine (37) = norepinephrine (36) > 
isoproterenol (38) in terms of potency, and for the P-adrenoceptors, isoproterenol > 
epinephrine > norepinephrine.57 a-Adrenoceptors mediate mostly excitatory functions that 
include vasoconstriction, uterine musculature contraction, urethra contraction, and pupil 
dilation, and one inhibitory function, intestinal r e l a x a t i ~ n . ~ ~  p-~drenoce~tors  mediate 
mostly inhibitory functions that include vasodilation, uterine musculature relaxation, 
bronchodiliation, and an excitatory fbnction, cardiac function.55 a2-Adrenoceptors are 
classified into three subtypes: a2*-, a 2 ~ - ,  and a2c-adrenoceptor subtypes. As mentioned 
earlier, GPCRs mediate their physiological effects via second messenger systems (Figure 
5).  In the case of a2-adrenoceptors, the second messenger systems that are involved are 
inhibition or stimulation of adenylyl cyclase, activation of receptor-operated K+ channels, 
and inhibition of voltage-gated ca2+  channel^.'^ It has been suggested that other G-protein 
dependent signaling pathways are mediated by activation of phospholipase D, stimulation 
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of phospholipase A2 activity, and increased intracellular ca2+ a ~ a i l a b i l i t ~ . ~ ~ . ~ ~  The a 2 -  
adrenoceptors are coupled to Gi/, types of G-proteins, which cause the inhibition of 
adenylyl cyclase and lead to a decrease in cAMP levels.' These G-proteins are sensitive to 
inactivation by pertussis toxin, which prevents the dissocigtion of the a subunit fiom the 
subunit.58 However, it has been shown that a2-adrenoceptors are also coupled to the 
stimulation of adenylyl cyclase via G,-proteins in some cells transfected with a 2 -  
adrenoceptors which leads to an elevation in CAMP levels.59 All three subtypes are 
involved with decreasing cAMP levels, but it has been shown that only a2~- and a2c- 
adrenoceptors inhibit ca2+ channels and activate K+ channels.56 
Figure 5. Schematic diagram of the G-protein cycle.59 PTX: Pertussis toxin and CTX: cholera 
toxin. 
2. Structure 
The arrangement of the structure of a2-adrenoceptors corresponds to a model of the 
protein rhodopsin, which has been extensively studied, and several subtypes have been 
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identified.'" general, Q-adrenoceptors have seven transmembrane-spanning 
hydrophobic regions (TM 1 -TM7), with hydrophilic intracellular and extracellular 
The transmembrane regions are made up of 20- to 25-amino acids forming alpha helices 
that are embedded in the membrane.8 The &-adrenoceptor subtypes share about 75% 
amino acid identity in their transmembrane regions.' The largest difference among the a2- 
adrenoceptor subtypes occurs in the N-terminus and in the third intracellular loop between 
TM5 and T M ~ . ~ ~  Among the subtypes, they share less than 25% sequence identity in the 
third intracellular loop.58 The third intracellular loops of the three subtypes vary in 
sequence and in the number of amino acids: a2*-adrenoceptors consist of 157 amino 
acids, a2B-adrenoceptors consist of 173 amino acids, and azc-adrenoceptors consist of 148 
amino acids (Table 4)." 
Table 4. Summary of a2-Adrenoceptor Subtype ~haracteris t ics .~~ 
a7 A a?,- 
Human chromosome 
Structure 
number of amino acids 
transmembrane domains 
number of amino acids in 
third intracellular loop 
glycosylated 
palmitoylated 
Second messenger systems G$,: .L CAMP. Gil,: CAMP Gi,,: CAMP. 
inhibit ca2' inhibit ca2' 
channels, open channels, open 
K' channels K' channels 
34 
Interestingly, the third intracellular loop of the a2B-adrenoceptor subtype contains 
a higher number of glutamic acid residues (13%) when compared to azA-adrenoceptors 
(6%) and a2c-adrenoceptors (3%).60 In this region, which is only seen in a2~- 
adrenoceptors, there is a stretch of 12 consecutive glutapic acid residues." The third 
intracellular loop is about two to three times longer in the a2-adrenoceptors than in the 
corresponding loops of the a , -  and P-adreno~e~tors. '~ The second and third intracellular 
loops are involved with G-protein  interaction^.^^ The @A-adrenoceptor subtype consists of 
450 amino acids and is glycosylated on the N-terminus and palmitoylated on the C- 
The ~x~~-adrenoceptor subtype also consists of 450 amino acids and is 
palmitoylated on the C-terminus but is not glycosylated, whereas the a2c-subtype consists 
of 461 amino acids and is only glycosylated on the  terminus.^^"^ The palmitoylated 
cysteine residue in the a z ~ -  and azB-adrenoceptors attaches the receptor to the lipid bilayer 
of the cell membrane." It is suggested that some of the TM regions form a ligand-binding 
pocket located in the upper part of the hydrophobic core of the receptor (Figure 6).58 There 
is a disulphide bridge between two cysteine residues in TM3 and the second extracellular 
loop that is important for maintaining the overall protein structure.58 
Extracellular 
Plasma 
membrane 
Figure 6. Model of a ligand binding to a GPCR.~* 
All of the a2-adrenoceptor subtypes have been cloned from human, rat, mouse, and 
guinea pig  source^.^^'^^ The human a2-adrenoceptor subtypes have been designated a2- 
C10 (a2~) ,  a2-C2 (a2B), and a2-C4 (a2c). These designations are based on their 
chromosomal location on the human gene that encodes these subtypes.57 These subtypes 
share approximately 50% amino acid identity. Also, the porcine and bovine a 2 ~ - ,  chicken 
a2,4-, opossum a2c- and fish azc-adrenoceptors are orthologs and have been cloned.58 The 
rodent a2~-adrenoceptor was initially classified as a new subtype, the azD-adrenoceptor, 
but is now acknowledged as the rodent homolog of the human aA-adrenoceptor subtype.58 
The difference in these two subtypes is their affinity for an a2-adrenoceptor ligand. The 
rat a20-adrenoceptor subtype has a lower affinity for the nonselective a2-adrenoceptor 
antagonist yohimbine (39) than does the human ~cz~-adrenoce~tor.~* 
Yohimbine (39) 
3. Pharmacology 
a*-Adrenoceptors play a major role in mediating several physiological effects in 
the CNS. The various a2-adrenoceptor subtypes are distributed throughout the brainstem 
and spinal cord. In rats and mice, a2-adrenoceptors are localized throughout the same 
regions in the CNS." The arA-adrenoceptor subtype is located in the brainstem, cerebral 
cortex, locus coeruleus, amygdala, pontine nuclei, nucleus tractus solitarii, dorsal horn, and 
the dorsal root ganglia.6'?62 The ~t~~-adrenoceptor subtype is found mainly in the thalamus, 
and the ~t~~-adrenoceptor  subtype is found in the olfactory bulb, cerebral cortex, 
hippocampus, striaturn, and dorsal root In humans, the &*-subtype is 
distributed in the cerebral cortex, brainstem, hippocampus, amygdala, locus coeruleus, and 
dorsal root ganglia. 55,64,65 The a2B-adrenoceptor subtype is distributed in the thalamus, 
dorsal root ganglia, and throughout the spinal cord, and the azc-adrenoceptor subtype is 
distributed in the cerebral cortex and lumbar spinal cord. 55,64,65 
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Both a2-adrenoceptor agonists and antagonists have been analyzed to study the 
functions of a2-adrenoceptors. There are various functional assays that have been used in 
order to characterize a2-adrenoceptor ligands as agonists or antagonists. a2-Adrenoceptors 
modulate blood pressure, therefore one in vivo assay that has been used is a measurement 
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of pressor responses in a pithed rat In this model, the spinal cord of the rat is 
severed by inserting a steel rod, which acts as a stimulating electrode, down the spinal 
Then, arterial pressure is monitored by cannulating the right carotid artery. When 
an a2-adrenoceptor agonist is administered, it causes a decrease in blood pressure (or a 
hypotensive effect).66 Thus an @-adrenoceptor antagonist blocks this decrease in blood 
pressure. An alternative method to studying pressor responses is in anaesthetized rats.67 
The only difference in this model is that the rats are anaesthetized with pentobarbital 
instead of severing the spinal cord. As seen in the pithed rats, a2-adrenoceptor agonists 
produce a hypotensive effect.67 An in vitvo assay used for Q-adrenoceptors is contraction 
of the saphenous vein.56 In this assay, an e-adrenoceptor ligand is administered and if it 
causes the saphenous vein to contract, it is referred to as an agonist.56 a2-Adrenoceptor 
ligands are characterized as antagonists if they can block this contraction. These functional 
assays have been helpful in further understanding the physiological effects produced by 
a2-adrenoceptors. 
4. Ligands and SAR 
a) Agonists 
Currently, there are several drug classes that bind at a2-adrenoceptor subtypes 
nonselectively. Both nonselective agonists and antagonists have a variety of therapeutic 
applications. The first drug class found to bind at a2-adrenoceptors was the 
phenylethylamines.68 This class consists of the two endogenous agonists norepinephrine 
(36, Ki = 81 nM) and epinephrine (37, Ki = 15 n ~ ) . ~ ~  However, these two agonists bind 
nonselectively at a , - ,  a f - ,  and P-adrenoceptors. Increasing the steric bulk of the N- 
substituent to ethyl (40), isopropyl (38), or tert-butyl (41) eliminates affinity for a2 -  
adrenoceptors (Ki > 10,000) .~~ Maintaining the catechol moiety is also important for 
binding at these receptors.68 Removal of the P-hydroxyl group usually reduces the affinity 
at a2-adrenoceptors, but dopamine (42, Ki = 250 nM) retains high affinity." The 
phenylethylamines have been shown to possess higher affinity for P-adrenoceptors when 
compared to a2-adrenoceptors. 
Dopamine (42) 
The next major class of compounds that binds at a2-adrenoceptors is the 
imidazolines. Most of the representative agents in this class are partial agonists, whereas 
others are either full agonists or antagonists.68 In the imidazoline class, the presence of a 
catechol moiety results in high affinity agents but is not required for binding at a2- 
adren~ce~tors." An important nonselective a2-adrenoceptor agonist in this class is 
clonidine (43, Ki = 1.8 nM); 43 is an aminoirn ida~ol ine .~~>~~ In general, the 
aminoimidazolines are highly selective for a2-adrenoceptors and when they bear 
substituents at the 2- andlor 4-positions they can readily cross the blood-brain barrier.68 An 
analog of clonidine, ST-91 (44), was also found to bind at a2-adrenoceptors with high 
affinity as seen with clonidine and also behaves as an a2-adrenoceptor agonist.@ Since 
Clonidine (43) ST-91 (44) 
clonidine (43) possesses such high affinity at a2-adrenoceptors, its structure has been used 
as a model to develop novel ligands.70 For example, Hlasta et studied a series of 
indolin-2-yl (Table 5) and tetrahydroquinolin-2-yl imidazolines. It has been suggested that 
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the ortho di-chloro substitution pattern of clonidine (43) helps to restrict the imidazoline 
ring in a position that is perpendicular to the 2,6-dichlorophenyl ring.70 This conformation 
is supposed to be responsible for the a2-adrenoceptor agonist activity of ~lonidine.~'  It was 
shown that the cis-indoline 45 (Ki = 6.9 nM) possesses high affinity that was comparable 
with clonidine. The trans-indoline 46 (Ki = 72.3 nM), which is less sterically hindered, 
showed a decrease in affinity at a2 -adreno~e~to r s .~~  Various heteroatoms were introduced 
into the side chain that was added to the indoline at the 2-position.70 These additions to the 
indoline resulted in high affinity for these agents at a2- a d r e n o ~ e ~ t o r s . ~ ~  Ring expansion of 
the indolines to, for example cis-tetrahydroquinoline 47 (Ki >10,000 nM) resulted in 
elimination of affinity.70 
Table 5. Observed Binding Affinities of Indolin-2-yl imidazolines at a 2 - ~ d r e n o c e ~ t o r s . ~ ~  
CH, 
45-46 and 48-53 
~~- 
45 H 
46 H 
48 CH3 
49 CH2CH=CH2 
50 CH2CH2CH2 
51 CH20CH3 
52 CH2SCH3 
53 CH2N(i-Pr)2 
clonidine 
It has also been suggested that the structure of clonidine (43) has to be in a specific 
conformation to interact with the receptor.71 The basic nitrogen must lie at a short distance 
above the plane of the aromatic ring with the plane of the imidazoline ring perpendicular to 
the plane of the aromatic ring.71 This conformation prevents any resonance interaction 
between the aromatic portion and the imidazoline ring.71 So in order to study this 
conformation, a series of spiro-imidazolines was developed and analyzed (Table 6). The 
parent compound (i.e., 54) was found to bind at azA-adrenoceptors with high affinity (Ki = 
34 nM) and at ~t~~-adrenoceptors with decreased affinity (Ki = 275 n ~ ) . ~ '  Adding a fluoro 
group at the R1 position increased the binding affinity at both a2A- and ~t~~-adrenoceptors 
(55, Ki = 12 and 152 nM, respectively).71 Chloro groups in the R2 and Rq positions also 
increased the affinity at both a2,4- and a2B-adrenoceptors (56, Ki = 3 and 95 nM, 
respectively).71 Adding an electron donating group in the R1 position, a methoxy group 
(i.e., 57), decreased the affinity at the a2A-adrenoceptors (Ki = 51 nM) but had a similar 
affinity at ~x~~-adrenoceptors (Ki = 99 nM) when compared to ~ 6 . ~ '  A methoxy group in the 
R2 position (i.e., 58) increased the affinity at azA-adrenoceptors but decreased the affinity 
at ~x~~-adrenoceptors (K,= 18 and 193 nM, respectively).71 More analogs were studied and 
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it was shown that this conformation might be one of the ways that clonidine (43) binds at 
both a2A- and a2B-adrenoceptors. 7 1 
Table 6. Observed Binding Affinities of Irnidazolines at a2A- and a 2 ~ - ~ d r e n o c e ~ t o r s . ~ '  
Oxyrnetazoline (62) is another example of an imidazoline but it shows selectivity 
among the a2-adrenoceptor subtypes. Oxymetazoline (62) binds with higher affinity at 
a2A-adrenoceptors (Ki = 5.6 nM) than at a 2 B -  and a2c-adrenoceptors (Ki = 350 and 72 nM, 
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respectively)." This agent is one of the few selective a2*-adrenoceptor agonists that has 
been developed. Although oxymetazoline (62) is selective among the a2-adrenoceptor 
subtypes, it also binds at a,-adrenoceptors (Ki= 29.8 n ~ ) . ~ ~  
Oxyrnetazoline (62) 
The substituted guanidines are a small class consisting of a couple of ligands that 
bind at a2-adrenoceptors nonselectively. Two representative agonists in this class are 
guanabenz (63, Ki = 16.7 nM) and guanfacine (64, Ki = 24.9 n ~ ) . ~ *  It has been shown that 
the substituted guanidines also bind at another receptor population, the imidazoline 
receptors. 68 
Guanabenz (63) Guanfacine (64) 
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An analog of the imidazolines, medetomidine (65, Ki = 25 nM), is a highly potent 
nonselective a2-adrenoceptor agonist.68 A series of conformationally restricted analogs of 
medetomidine was developed and analyzed as possible a2-adrenoceptor agonists.72 For 
Medetoniidine (65) 
example, tetralin 67 (Table 7) displayed about 4-fold lower affinity than 65. In this 
tetralin series, the 5-methoxy analog retained affinity at a2-adrenoceptors (66, Ki = 98 
n ~ ) . ~ ~  Other analogs are shown in Table 7.72 In the 3,4-dihydronapthalene series (Table 
7), a methoxy group in the 5-position decreased the affinity by more than 50-fold (72, Ki = 
1420 n ~ ) . ~ ~  A methyl group (73, Ki = 3 1 nM) in the 5-position resulted in similar affinity 
as medetomidine (65).72 However adding methyl groups in the 5- and 7-positions resulted 
in a decrease in affinity (74, Ki = 232 As seen in the 5-substituted tetralin series, a 
methoxy group in the 6- or 7-position decreased affinity (75, 76, Ki = 580 and 1570 nM, 
respectively).72 The 4-methylindan analog 77 (Ki = 8.8 nM) displayed enhanced affinity 
relative to 65.72 
Table 7. Observed Binding Affinities of Conformationally Restricted Analogs of 
Medetomidine at a 2 - ~ d r e n o c e ~ t o r s . ~ ~  
In a previous study, Gentili et a1.73 showed that modifying the structure of 
imidazoline compounds resulted in a significant difference in their affinity at a2- 
adrenoceptors. It was found that imidazolines 78 and 79 were antagonists at a 2 -  
adrenoceptors and weak agonists at a, - a d r e n ~ c e ~ t o r s . ~ ~  From this study, biphenyline (80) 
was also developed and found to be selective for a2-adrenoceptors and also behaved as an 
@-adrenoceptor agonist in in vitro assays.73 Biphenyline (80) was obtained by introducing 
a phenyl ring in the ortho position of the 2-[I-@henoxy)ethyl]-imidazoline basic 
structure.73 It was suggested that this phenyl group might be responsible for the agonist 
Biphenyline (80) 
activity seen with biphenyline Various modifications were made to the phenyl ring 
in the ortho position and resulted in a series of biphenyline analogs (Table 8).73 The 
affinity and intrinsic activity were measured for these biphenyline analogs as well as 
biphenyline Biphenyline (80) was found to bind with higher affinity at a 2 ~ -  
adrenoceptors when compared to a 2 ~ -  and a2c-adrenoceptors (Ki = 47, 501, and 199 nM, 
respectively).73 It also behaved as an agonist at both and azc-adrenoceptors and a 
partial agonist at azB-adrenoceptors.73 Therefore a major focus for this study was to modify 
the phenyl group in order to develop subtype selective a2-adrenoceptor agonists. The first 
approach was isosteric substitution with a pyridine or thiophene nucleus.73 The pyridine 
derivatives 81 and 83 resulted in lower affinity at a2-adrenoceptors when compared to 
Table 8. Observed Binding Affinities of Biphenyline Analogs at a2-Adrenoceptor 
ia = intrinsic activity, NA = not active (ia < 0.3) 
biphenyline (80) and were inactive at all three subtypes.73 However, 82 possessed higher 
affinity at a2-adrenoceptors than the other pyridine derivatives and showed selectivity at 
azc-adrenoceptors.73 Compound 82 behaved as an agonist at a2c-adrenoceptors and a 
partial agonist at the other subtypes.73 The thiophene nucleus possesses aromaticity that is 
comparable to that of a phenyl ring.73 Both 84 and 85 behaved as agonists at a2A- and a2c- 
adrenoceptors and showed more selectivity in affinity for the ~ t ~ ~ - a d r e n o c e ~ t o r . ~ ~  The next 
approach was to incorporate various substitution at the ortho, meta, and para positions of 
the phenyl ring. A methyl group was added to the ortho, meta, or para position (86, 87, 
and 88, respectively) and none of these compounds were active at a2~- or a 2 ~ -  
adrenoceptors but behaved as partial agonists at a2c-adrenoceptors.73 When a hydroxy 
group was added at these three positions (89, 90, and 91), the only active compound was 
the m-hydroxy derivative 90 (K, = 18 nM, ia = 1.15) that behaved as a h l l  agonist with 
high affinity at azc-adrenoceptors.73 To further test the possible role that an electronic 
effect has on binding and agonist activity, a nitro group was added at the ortho, meta, and 
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para positions (92, 93, and 94, respectively).73 All three nitro derivatives were inactive at 
73 a2,4- and a 2 ~ -  adrenoceptors. However, the m-nitro derivative 93 was the only nitro 
derivative that showed any activity at a2c-adrenoceptors.73 Since the meta position seemed 
to be optimal for agonist activity, several other substituents were introduced at this 
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position. An amino derivative 95 possessed moderate affinity for all three a2-adrenoceptor 
subtypes but behaved as a partial agonist at a2,4- and a 2 ~ -  a d r e n ~ c e ~ t o r s . ~ ~  Addition of a 
fluoro group in the meta position, 96, showed an increase in affinity compared to 
biphenyline (80) and behaved as a full agonist at a2c-adrenoceptors and as a partial agonist 
at a2A-adrenoceptors.73 This was the first series of a2-adrenoceptor ligands that showed 
subtype selectivity for ~t~~-adrenoceptors 
Currently, there are available a2-adrenoceptor agonists that bind nonselectively at 
the a2-adrenoceptor subtypes. However, there are still only a limited number of agonists 
that show subtype selectivity for ~~~~-adrenocep to r s  versus a2B- and a2c-adrenoceptor 
subtypes. Although these agonists show subtype selectivity among the a2-adrenoceptor 
subtypes, they also bind at other receptor populations (i.e., 5-HT and a,-adrenoceptors). 
Still, there is no strictly subtype-selective a2A-adrenoceptor agonist that has been 
developed. There are also no subtype-selective azB-adrenoceptor agonists available. 
Recently, subtype selective a2c-adrenoceptor agonists have been developed and might be 
used to determine the physiological effects of azc -adren~ce~ to r s .~~  Selective a2-  
adrenoceptor subtype agonists can help to further understand the physiological effects of 
each subtype and also to manage any disorders that are mediated by the a2-adrenoceptor 
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subtypes. There is an increasing clinical, and basic science, need for selective a2- 
adrenoceptor subtype-selective agonists. 
b) Antagonists 
Many a2-adrenoceptor antagonists have been developed over the years. These 
antagonists have been used to classify the a2-adrenoceptor subtypes via radioligand 
binding studies. a2-Adrenoceptor antagonists come from a variety of chemical classes. 
Some representative a2-adrenoceptor antagonists include yohimbine (39), rauwolscine 
(97), imiloxan (98), and SK&F 86466 (99). Yohimbine (39), an indole alkaloid that has 
been isolated from Pausinystlia yohimbe bark and Rauwolfia root, has been used in herbal 
medicines for centuries.' 
'0 
Rauwolscine (97) 
C H ~  
Imiloxan (98) 
Yohimbine (39) is an a2-adrenoceptor antagonist that binds at the a2,-adrenoceptor 
subtype (Ki = 7.5 nM), a2~-adrenoceptor subtype (Ki = 4.6 nM), and ~t~~-adrenoceptor 
subtype (Ki = 2.3 nM) with similar affinity.68 Since yohimbine (39) binds at a2- 
adrenoceptors with such high affinity, other yohimbine derivatives were examined and 
characterized as a2-adrenoceptor antagonists. Rauwolscine (97) is also an alkaloid that 
belongs to the same family as yohimbine, the yohimbanes.68 Rauwolscine (97) binds at the 
a2-adrenoceptor subtypes nonselectively: a2,-adrenoceptor subtype (Ki = 4.6 nM), a2~- 
adrenoceptor subtype (Ki = 4.7 nM), and ~t~~-adrenoceptor subtype (Ki = 1.0 nM), and 
with an affinity comparable to that of yohimbine (39).68 Several other analogs of 
yohimbine, raubasine (100) and akuammingine (101), are also selective a2-adrenoceptor 
 antagonist^.^' Both of these analogs have been isolated from the same sources as 
Raubasine (100) Akuammingine (1 01) 
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yohimbine (39) and are known as h e t e r ~ ~ o h i m b i n e s . ~ ~  Raubasine (100) binds at all of the 
a2-adrenoceptor subtypes with high affinity: ~~~-adrenocep to r  subtype (K, = 8.2 nM), a 2 ~ -  
adrenoceptor subtype (Kl = 14.5 nM), and azc-adrenoceptor subtype (Ki= 5.0 JM).~' 
Akuammingine (101) binds at each a2-adrenoceptors with lower affinity than yohimbine 
(39): a2~-adrenoceptor subtype (K, = 106 nM), ~x~~-adrenoceptor subtype (K, = 116 nM), 
and a2c-adrenoceptor subtype (K, = 28 n ~ ) . ~ '  
Imiloxan (98) is an a2-adrenoceptor antagonist that belongs to another class, the 
ben~od ioxans .~~  Imiloxan (98) is a benzodioxanyl N-ethylimidazole that binds selectively 
at the a2B-adrenoceptor subtype (K, = 136 nM) compared to a2A- and a2c-adrenoceptor (Ki 
= 1701 and 1056 nM respectively).75 Imiloxan (98) has been used to characterize the 
physiological functions of a2B-adrenoceptors, since it is the only available a 2 ~ -  
adrenoceptor-selective antagonist. When imiloxan (98) originally was implicated as a 
selective a2e-adrenoceptor antagonist, its binding activity was studied only at a2~- and 
a2B-adrenoceptors.76,77 However, it has been shown that imiloxan (98) blocks the 
antinociceptive activity of the a2-adrenoceptor agonist, ST-91 (44), whose actions are 
thought to be mediated primarily through the w-adrenoceptor subtype.78 Currently, there 
is great controversy for which a2-adrenoceptor subtype imiloxan (98) is truly selective: 
a 2 B -  or a2c-adrenoceptors. Idazoxan (102), a benzodioxanyl imidazoline, is also an az- 
adrenoceptor antagonist. Unlike imiloxan (98), idazoxan (102) binds nonselectively at the 
a2-adrenoceptor subtypes: a2A-adrenoceptor subtype (Ki = 21 nM), azB-adrenoceptor 
subtype (Ki = 43 nM), and azc-adrenoceptor subtype (Ki = 35 nM).59 
Idazoxan (1 02) ' 
Another class of a2-adrenoceptor antagonists are the benzazepines (Table 9).68 
SK&F 86466 (99) shows moderate selectivity for a2-adrenoceptors versus a,- 
adrenoceptors, but binds at the a2-adrenoceptor subtypes nonselectively: a2*-adrenoceptor 
subtype (Ki = 9.4 nM), a2~-adrenoceptor subtype (Ki = 16 nM), and a2c-adrenoceptor 
subtype (Ki = 20 n ~ ) . ~ ~  SK&F 86466 (99) has been used to subclassify a2-adrenoceptor 
physiological responses in functional assays.68 A heterofused analog, SK&F 104856 (103) 
shows approximately 8-fold selectivity for the a2B-adrenoceptor subtype (K; = 3.4 nM), 
when compared to ~t~~-adrenoceptor subtype (Ki = 24 nM) and a2c-adrenoceptor subtype 
(Ki = 2 1 n ~ ) . ~ ~  Several related 3-benzazepine derivatives have been developed; some are 
shown in Table 9.68 
Table 9. Observed Binding Affinities of 3-Benzazepine Derivatives at a2- 
Adrenoceptor 
A well-known a2-adrenoceptor antagonist belongs to a group, the quinazolines, that 
mostly behaves as a]-adrenoceptor antagonists. Quinazolines do not discriminate between 
the a]-adrenoceptors but several, including prazosin (107), have been shown to bind at a2- 
adrenoceptors. Evidence shows that prazosin (107) binds selectively at both a2B- and a2c- 
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adrenoceptors with high affinity (Ki = 30.6 and 10.7 nM, respectively) when compared to 
~t~~-adrenoceptors (Ki = 302 n ~ ) . ~ ~  
f i ~ ,  
Prazosin (1 07) 
In general, a number of a2-selective antagonists have been identified, but with the 
exception of imiloxan (98), few show selectivity within the a2-adrenoceptor family. 
Furthermore, it is currently unknown whether imiloxan is an a 2 ~ ,  a 2 ~  or a2Bla2c-selective 
antagonist. 
c) Therapeutic Application of a*-Adrenoceptor Agents 
a2-Adrenoceptor agonists and antagonists have a wide range of therapeutic 
applications. a2-Adrenoceptor agonists have been used in the treatment of hypertension 
for many years.' This is due to the fact that a2-adrenoceptors, which are present on blood 
vessels, can mediate vasoconstriction.68 Clonidine (43), guanabenz (63), and guanfacine 
(64) are still being used clinically for the treatment of hypertension.' All of these agents 
also bind at imidazoline receptors and are thought to require both components, a2-  
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adrenoceptors and imidazoline receptors, to lower and maintain blood pressure.79 
However, some of the drawbacks of these antihypertensives are that they cause sedation, 
bradycardia, and mental depression.79 a2-Adrenoceptors are also involved with non- 
insulin-dependent diabete~.~' , '~ Activation of a2-adrenoceptors has been shown to inhibit 
the secretion of insulin from pancreatic islet Several a2-adrenoceptor antagonists, 
rauwolscine (97) and idazoxan (102), enhanced glucose-induced insulin secretion in the 
Yohimbine (39) increases plasma insulin, and inhibits epinephrine-induced 
hyperglycemia in mice.68979 Therefore, blocking R-adrenoceptors seems to play a role in 
selectively enhancing glucose-stimulated insulin secretion in this type of diabetes.79 
Another possible target of a2-adrenoceptors' therapeutic applications is obesity. It 
has been shown that stimulating a2-adrenoceptors causes an inhibition of lipolysis in 
isolated human adipocytes. This stimulation of a2-adrenoceptors could possibly be used to 
promote weight l o ~ s . ~ ' , ~ ~  In rodents, SK&F 86466 (99) can block R-adrenoceptors which 
then stimulates epinephrine-induced lipolysis.68~79 Studies have shown that long-term 
treatment with SK&F 86466 (99) results in a dose-related loss in body weight that was 
independent of the amount of food i n t a l ~ e . ~ " ~ ~  Since activation of central @-adrenoceptors 
results in sedative effects, a2-adrenoceptor agonists have been clinically used in 
a n e ~ t h e s i a . ~ ~  Clonidine and other a2-adrenoceptor agonists are being used as adjuncts to 
general a n e ~ t h e s i a . ~ " ~ ~  a2-Adrenoceptor agonists, detomidine and medetomidine (65), are 
being used as veterinary  anesthetic^.^^'^^ Evidence shows that pretreatment with 
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medetomidine (65) reduces the requirement for using gaseous anesthetics in both rats and 
The noradrenergic system inhibits nociception that is primarily mediated by a2-  
adrenoceptors. Noradrenergic neurons descend from the brainstem to the spinal cord and 
terminate in the dorsal horn." This descending inhibitory pathway modulates pain by 
constituting a gating mechanism that controls impulse transmission in the dorsal horn." 
Norepinephrine (36) plays an important role in the n~odulation of pain transmission in the 
brain and spinal cord." 1.t. administered norepinephrine (36) produces antinociceptive 
activity in rodenk8 Q-Adrenoceptor agonists produce antinociception through the 
activation of the noradrenergic system.'' Clonidine (43), the most studied a2-adrenoceptor 
agonist, produces antinociception both in rodents and humans.' Evidence shows that 
clonidine produces its analgesic activity when administered systemically, epidurally, and 
intrathe~all~.' The a2-adrenoceptor's role in nociception has been studied in nociceptive 
tests in rodents, especially thermal nociceptive tests. In both the hot-plate and tail-flick 
tests, clonidine produces dose-dependent antinociception when given via the intravenous 
(i.v.), i t . ,  or s.c. route.81 These studies showed that clonidine-induced antinociception is 
mediated by supraspinal and spinal a2-adrenoceptor sites. Also, ST-91 (44), an analog of 
clonidine, produced antinociception in rats when administered via the i t .  route.'* 
Activation of a2-adrenoceptors causes hyperpolarization of neurons by opening K' 
channels, which seems to share a role in the antinociception produced by a2-adrenoceptor 
agonists.83 Galeotti et showed that clonidine-induced antinociception was enhanced 
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by the KATP channel openers minoxidil, pinacidil, and diazoxide in both the hot-plate and 
tail-flick tests, whereas the KATP channel blocker gliquidone attenuated the antinociceptive 
activity of clonidine (43).83 a2-Adrenoceptors seem to be involved in the antinociception 
mediated by other descending inhibitory systems. 5-Methoxy-N,N-dimethyltryptamine (5- 
MeO-DMT), a 5-HT agonist, produced a dose-dependent antinociception that was blocked 
by yohimbine (39).84 This study suggested that 5-HT-induced antinociception might be 
dependent on the descending noradrenergic system. In another study, Svokos et al? 
showed that i.c.v. administered improgan, a histamine-2 receptor ligand, produced 
antinociceptive activity in rats. When i.p. or i.t. administered yohimbine (39) was given, 
yohimbine (39) attenuated the antinociceptive activity of improgan.85 However, i.c.v. 
administered yohimbine (39) did not attenuate the antinociceptive activity of improgan.85 
These results showed that a2-adrenoceptors play a role in antinociception induced by 
histamine receptors but only the spinal az-adrenoceptors were involved. a2-Adrenoceptors 
might also be involved in GABAB receptor-induced antinociception. Sabetkasai et aLg6 
showed that i.p. administered baclofen, a representative GABAB agonist, produced 
antinociception in mice in the tail-flick test. The antinociceptive activity of baclofen was 
blocked by i.p. administered yohimbine (39).86 This study further demonstrated the various 
systems that induce antinociception might be influenced by the noradrenergic system 
(Figure 7). 
DESCENDING INHIBITION DESCENDING FACILITATION 
Figure 7. Schematic diagram of noradrenergic system modulating noci~e~tion.~ This figure is used 
to show the involvement of the noradrenergic system with other neurotransmitters. 
Thermal nociceptive tests were also used to further understand which a2- 
adrenoceptor subtypes might be involved in antinociception mediated by a2-adrenoceptors. 
In a study by   ill an,^^ S.C. administered UK 14,304 (108), an a-adrenoceptor agonist, 
produced antinociceptive activity in mice in the hot-plate test. Several a2-adrenoceptor 
antagonists, both nonselective or subtype selective, were used to study a;?-adrenoceptor 
subtype in~olvement .~~  The nonsubtype selective a2-adrenoceptor antagonist idazoxan 
(102) blocked the antinociceptive activity of LTK 14,304 ( l 0 8 ) . ~ ~  Both BRL 44408 (109) 
and RX 821002 (110), a2~-adrenoceptor antagonists, also blocked UK 14,304-induced 
antino~ice~tion.~' However, BRL 4 1992 (1 11) and ARC-239 (1 12) and prazosin (107), 
selective a 2 ~ -  and a2c-adrenoceptor antagonists, did not have any effect on the 
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antinociceptive activity of UK 14,304.~~ This study suggested that among the supraspinal 
a2-adrenoceptor subtypes, only a2A-adrenoceptors are involved with antinociception 
induced by a2-adrenoceptor agonists. 
UK-14,304 (108) BRL 44408 (109) 
0 C N H  
RX 821002 (110) BRL 41992 (111) 
Figure 8. Subtype selective a2-adrenoceptor ligands.87 
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All of the previous studies in the hot-plate test showed that i.t. administered 
clonidine (43) and ST-91 (44) produced dose-dependent antinociception that activated 
supraspinal Q-adrenoceptor  site^.^'-^^ However, it was also shown that the it.- 
administered a2-adrenoceptor agonist dexmedetomidine was inactive in the hot-plate test 
but active in the tail-flick test.88 This could be due to the fact that clonidine (43) and ST-91 
(44) are very lipid soluble compounds. This means that when these agents are 
administered directly into the spinal cord they are absorbed rapidly into the blood and 
diffused to other parts of the CNS.~  This allows these agents to activate a*-adrenoceptors 
that are located in the brain. This idea was supported by the study by Ossipov et d8' that 
showed that i.v. administered clonidine (43) produces antinociception in both the hot-plate 
and tail-flick tests. There has been controversy about the actual involvement of 
supraspinal a2-adrenoceptors in the antinociception induced by spinally-administered a2- 
adrenoceptor agonists. In another study, it was shown that i.t. administered clonidine (43) 
still produced potent antinociceptive activity after transection of the spinal cord.8 This 
suggests that although supraspinal a2-adrenoceptors could possibly contribute to 
antinociception, activation of these sites might not be required to produce the maximal 
antinociceptive effect of clonidine (43). 
Earlier studies showed that a2-adrenoceptors have influence on the mediation of 
opioid-induced antinociception. Norepinephrine (36) is a modulator of the antinociceptive 
activity produced by opioid agonists in the spinal cord.*' 1.t. administered yohimbine (39) 
blocks the antinociceptive activity of i.t.-administered morphine.89 This evidence further 
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suggests that a2-adrenoceptors are involved in morphine-induced antinociception. 
However, naloxone, an opioid antagonist, did not attenuate the antinociceptive activity of 
clonidine (43).89 Coadrninistration of Q-adrenoceptor agonists and opioid agonists resulted 
in a greater-than-additive antinociceptive effect, or synergy.90 These agents could be 
administered in lower doses than when administered separately to produce an equivalent 
antinociceptive effect.90 This is important because this combination could be used 
clinically in pain therapies. The morphinelclonidine synergism allows a more efficient 
treatment that involves lower doses which probably was associated with lower risk of 
undesired side effects. Separately, morphine and clonidine (43) are being used clinically in 
the treatment of pain, including postoperative and cancer pain.90 Therefore, the morphine 
Iclonidine synergism has been extensively studied in rodents using both tail-flick and hot- 
plate tests. Systemically or spinally coadministered morphine and clonidine (43) produce a 
potentiation in antinociceptive activity in several animal s t ~ d i e s . * ~ - ~ '  Since morphine 
produces the development of tolerance, the synergistic effect of morphine and clonidine 
(43) was studied in mice that were either acutely or chronically tolerant to morphine.90 
Fairbanks and ~ i l c o x ~ '  showed that mice acutely tolerant to i.t.-administered morphine 
still produce a synergistic effect when morphine and clonidine (43) were coadministered 
via the i.t. route.90 Similar results were shown when the mice were chronically tolerant to 
i.t.-administered morphine.90 These results showed that even though tolerance develops 
from the use of morphine, coadministration of morphine and clonidine (43) could still be 
an efficient therapeutic treatment of pain. 
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Coadministration of clonidine (43) and morphine has been used clinically in 
patients for the treatment of postoperative pain. It was shown that epidural clonidine (3 
pglkg) plus morphine (0.05 mglkg) provided better postoperative analgesia than epidural 
morphine alone after a gastrectomy.92 Evidence shows that the combination of these two 
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analgesics can also be used in postcesarean analgesia.93 In a recent study, it was reported 
that the combination of subarachnoid morphine and clonidine (43) increased the duration 
of postcesarean analgesia when compared with morphine or clonidine (43) alone.93 This 
combination also reduced the opioid requirement and increased intraoperative sedation.93 
As mentioned earlier, studies have shown that the a2*-adrenoceptors are involved 
in antinociception. It was recently found that both a2B- and a2c-adrenoceptor subtypes 
could also play a role in mediating antinociception. Prazosin, which is selective for ( 3 2 ~ -  
and a2c-adrenoceptors, inhibited neurotransmitter release from spinal cord preparations.78 
This supports the idea of possible roles for both a2B- and a2c-adrenoceptors in 
antinociception. Sawamura et ~ 7 1 . ~ ~  showed that activation of a2B-adrenoceptors could 
mediate the antinociceptive activity of nitrous oxide, an adjunctive general anesthetic. In 
this study, null mice for the a2B-adrenoceptor subtype produced a reduced or absent 
analgesic response to nitrous oxide.94 
a2-Adrenoceptor agonists have been classified as being potent analgesics. 
Although a2-adrenoceptor agonists are being used therapeutically as analgesics, they still 
produce the undesired side effects of sedation, hypotension, and bradycardia. The use of 
a2-adrenoceptor agonists in combination with other clinically known analgesics has been 
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studied over the years. This allows a2-adrenoceptor agonists to be used therapeutically but 
in lower doses than those that prevent the development of undesired side effects. It has 
been shown that the a2*-adrenoceptor subtype is responsible for the hypotensive, sedative, 
and bradycardic actions associated with a2-adrenoceptor agonists.78 The development of 
a2-adrenoceptor agonists that are selective for a 2 ~ -  and/or a2c-adrenoceptors has become a 
major interest in the field of analgesia. 
D. Behavioral Tests for Nociception 
Measuring pain and analgesia in animals can be quite difficult. This is mainly 
because pain itself consists of a multiplicity of sensory entities.95 Also, the term "pain" is 
poorly defined when related to animals and their behavior.95 Pain is a subjective and 
personal psychological experience that cannot be measured directly in animals since an 
animal cannot describe how it feels.95 Therefore the term "pain" is usually avoided when 
describing the study of nociception in animal models,95 rather, the term "antinociception" 
is used. The antinociceptive effect of a test compound can be measured in animal models, 
and many factors can influence the outcome of the measurements in all animal models of 
n o ~ i c e ~ t i o n . ~ ~  Different species and strain of animals can have a major affect on the test 
results and is one of the more obvious factors.95 Another factor is that the time of day that 
the test is being conducted can produce a variation in results.95 Skin temperature of the 
stimulated area can influence the response to heat stimulus and is a factor that is important 
in thermal nociceptive  test^.^^,^^ Nociceptive tests can be useful when they are carefully 
performed. In nociceptive tests, various types of stimuli can be used. Specifically, in 
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thermal nociceptive tests, heat stimulus is used to induce a response to nociception in 
rodents.95 In thermal nociceptive tests, the stimulatory response is fixed and a standard 
response is defined.95 The duration of the heat stimulus, when the nociceptive response 
occurs, is measured, and thermal nociceptive tests mainly focus on the threshold of the 
heat stimulus required to induce a specific response.95 
Two well-known thermal nociceptive tests, tail-flick and hot-plate tests, have been 
used extensively in studying nociception and antinociception in rodents. Both the tail-flick 
and hot-plate tests were first described more than 60 years ago.95797 The tail-flick test was 
developed by D'Amour and and is used both in rats and mice. In the tail-flick 
test, radiant heat is focused on the rodent's tail and the time is measured for how long it 
takes for the animal to flick its tail away from the beam.95 This measurement is known as 
tail-flick latency, which is a measure of the sensitivity of the animal to heat stimulus. A 
maximal cut-off time is employed to prevent damage to the tail tissue.95 When an analgesic 
is administered to an animal, the agent can prolong the tail-flick latency. Spinal receptor 
sites are primarily involved in producing the nociceptive response seen in the tail-flick 
This idea was studied by transecting the spinal cord above the lumbar level." 
From such studies, it was shown that transection does not block the tail-flick response.95 
The tail-flick test is very reliable for studying nociception in rodents. However, there is 
one factor that can possibly result in a variation in data. The skin temperature of the 
animal is negatively correlated with tail-flick The tail-flick response is induced 
when the temperature at the nociceptors in the skin reach a critical The tail-flick 
latency depends strongly on the initial temperature of the skin which is influenced by local 
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blood f l o ~ . ~ ~ , ~ ~  SO certain manipulations that affect thermoregulation could cause 
variation in the results; these include lesions of the descending noradrenergic or 
serotonergic systems, transection of the spinal cord, administration of serotonin or 
norepinephrine receptor agonists or antagonists, and stress and handling of the animals.96 
Skin temperature is critical because reduction in the tail skin temperature can be 
interpreted as a n t i n o ~ i c e ~ t i o n . ~ ~  This problem can be avoided by recording the tail skin 
temperature and making corrections to the tail-flick latency accordingly.95 In contrast, 
Lichtman et a1. '0° showed that tail-flick latency is not influenced by the skin temperature 
of the rodent. Thus there is some controversy whether skin temperature actually causes a 
variation in results from tail-flick tests. 
The hot-plate test was developed by Woolfe and ~ a c ~ o n a l d " '  and is also 
extensively used in studying nociception in rodents. When first described, the hot-plate 
test measured the nociceptive response of rodents placed on a hot-plate apparatus at 
temperatures varying from 55 to 70 " c . ~ ~ '  97 The hot-plate test was later modified and a 
constant temperature of 55 "C is the temperature that is consistently used today.95,97 The 
latency to a variety of behavioral responses, including jumping, kicking, shaking of the 
foot, holding a foot tightly against the body, and licking the forepaw andlor the hindpaw, is 
used to measure the sensitivity to pain in rodents.97 Usually, hindpaw licking latency is 
used as the end-point.97 A maximal cut-off time is also employed in the hot-plate test. The 
hot-plate test focuses on the supraspinal receptors that are involved in mediating 
nociception and a n t i n o c i ~ e ~ t i o n . ~ ~  One problem seen in the hot-plate test is that mild 
analgesics possess no, or weak, antinociceptive activity at a constant temperature of 55 
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" c . ~ ~  Therefore, the increasing temperature hot-plate test was developed to solve this 
problem. 95,97,102 In this test, the temperature of the plate is set below the pain threshold and 
is gradually increased until the animal makes a response.95 The temperature at which the 
response occurs is then recorded as the nociceptive endpoint.95 The increasing temperature 
hot-plate test can be used with a conventional hot-plate which is initially set at 42- 43 "C 
and the cut-off temperature is 50- 52 " c . ~ ' , ~ ~  This test is more sensitive than the constant 
temperature hot-plate For example, earlier studies showed that the mild analgesics 
acetylsalicylic acid and paracetamol showed antinociceptive activity at 50 "C but not at 55 
or 59 "C. 95,97,102 
Thermal nociceptive tests are the most commonly used nociceptive tests in rodents. 
Since the development of both the tail-flick and hot-plate tests, there have been 
modifications made to each test to enhance the reliability of the results collected. The 
results from both of these tests might be affected by the skin temperature of the animal. 
However, the tail-flick test may be more susceptible to this problem than the hot-plate test. 
Use of the increasing temperature hot-plate test prevents the possible influence that skin 
temperature might have. In the case of the tail-flick test, this situation can be prevented by 
measuring the skin temperature of the animal before the test. However, this has been 
refuted.'OO Both thermal nociceptive tests have been extremely reliable in studying 
nociception and antinociception in rodents. 
111. Specific Aims and Rationale 
It was previously shown by Dukat et al.30 that MD-354 (21) binds at 5-HT3 
receptors with high affinity (K; = 35 nM). Additional binding studies showed that this 
compound also binds at az-adrenoceptors with high affinity.'03 MD-354 (21) binds 
selectively at a2B-adrenoceptors (Ki = 25 nM) when compared to a 2 ~ -  (K; = 825 nM) and 
~t~~-adrenoceptors (Ki = 140 nNI).lo3 As such, it might be viewed as the first example of a 
rather selective 5-HT3/a2B-adrenoceptor ligand. Because 5-HT3 receptors and a 2 ~ -  
adrenoceptors both have been implicated as playing a role in antinociception, MD-354 (21) 
might represent a novel, dual-mechanism type of analgesic agent. MD-354 (21) was first 
studied in the mouse tail-flick test. The antinociceptive activity of MD-354 (21) was 
compared with that of clonidine (43) as positive control.Io3 It was found that 1.0 mglkg of 
clonidine (43) produced 76% of the maximal possible effect (MPE) when administered via 
the S.C. route 20 min prior to the test.Io3 Other doses were evaluated and it was shown that 
clonidine (43) produced a dose-dependent antinociceptive effect (Figure 9).Io3 
Saline 
Clonidine Dose (mglkg) 
Figure 9. Antinociceptive actions of clonidine following S.C. administration in the mouse tail-flick 
assay. Asterisks denote significant differences compared to control group (i.e., saline); *P< 0.01 
and **P< 0.001 . I o 3  
Subcutaneous administration of MD-354 (21) at doses ranging from 1.0 to 30 
mglkg did not produce an antinociceptive effect when administered 45 min prior to testing 
(Figure 10). O3 Results were not different using various other pretreatment times. MD-354 
(21) was also examined as a possible antagonist of clonidine-induced antinoci~eption. '~~ 
When administered 45 min prior to testing, doses of 1.0, 3.0, and 10 mgkg of MD-354 did 
not antagonize the antinociceptive activity of the ED50 dose of clonidine (43) administered 
20 min prior to testing.lo3 Interestingly, a combination of the EDso dose of clonidine (43, 
MPE = 59%) and a dose of 10 mgkg of MD-354 (21, MPE = 8%) was found to enhance 
antinociception in It was also shown that an inactive dose of 0.25 mglkg of 
clonidine (43, W E  = 13%) in combination with MD-354 doses ranging from 1.0 to 30 
mgkg dose-dependently enhanced the antinociceptive effect in what appears to be a bell- 
shaped manner. (Figure 1 1).'03 
MD-354 Dose (mgtkg) 
Figure 10. Effect of MD-354 doses administered 45 rnin prior to testing in the tail-flick assay as 
compared to saline contr01.'~' 
MD-354 Dose (mglkg) + 0.25 mglkg of clonidine 
Figure 11. Potentiation of the antinociceptive actions of clonidine (0.25 mglkg) by MD-354 in 
the tail-flick assay. Asterisks denote significant differences compared to control group; *P< 0.05 
and **PC 0.01 . I o 3  
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Mechanistic studies were conducted to determine the mechanism behind the 
potentiating effect of clonidine antinociception by MD-354 in the mouse tail-flick test.'03 
Pretreatment with the putative azB-adrenoceptor antagonist imiloxan (6.0 and 10 mglkg 
i.p.) and the 5-HT3 receptor antagonist zacopride (0.5 and 1.0 mglkg i.p.) failed to attenuate 
the potentiation of clonidine antinociception (0.25 mglkg s.c.) by MD-354 (21, 6.0 mglkg 
s.c.).'03 These results suggest that neither a2B-adrenoceptors nor 5-HT3 receptors play a 
role in the potentiating effect of MD-354 (21). Since it is still controversial to which 
subtype of a2-adrenoceptors imiloxan binds, neither a 2 B -  nor a2c-adrenoceptors can be 
ruled out as playing a role in the potentiating effect by MD-354 (21). As previously 
mentioned, clonidine potentiates the antinociceptive effects of morphine. Since MD-354 
(21) enhances clonidine antinociception, the effect of MD-354 (21) on morphine 
antinociception was evaluated in the mouse tail-flick assay.'03 In a combination study, 
MD-354 (21) did not enhance the antinociceptive action of morphine.lo3 
The purpose of the present studies was to further examine MD-354 (21) in a 
different pain model (i.e., the hot-plate assay), and to further investigate its potential 
mechanism(s) of action accounting for its potentiating effect on clonidine antinociception 
(in both the tail-flick and hot-plate assay). MD-354 (21) will be studied in the mouse hot- 
plate assay so that the activity in both thermal tests can be compared. Using the hot-plate 
assay will help further understand the mechanism of potentiation of clonidine (43) by MD- 
354 (21). If MD-354 (21) is active by itself or in combination with clonidine (43) in the 
hot-plate assay, it would suggest that MD-354 (21) could possibly cross the blood-brain 
barrier and bind at supraspinal 5-HT3 andlor a2B-adrenoceptors. This will show that the 
potentiating effect by MD-354 (21) works via both spinal and supraspinal receptor sites. 
Then, mechanistic studies will be conducted to determine which receptor(s) (i.e., a2~- 
adrenoceptors andlor 5-HT3 receptors) are involved in this activity. If MD-354 (21) is 
inactive and does not potentiate clonidine-induced antinociception in the hot-plate assay, 
that could mean that MD-354 (21) is not lipophilic enough to cross the blood-brain barrier 
and may not reach the supraspinal receptors. MD-354 (21) is not a very lipophilic agent 
and has an experimentally determined Log P value of - 0 . 6 4 . ~ ~  This suggests that MD-354 
(21) might have difficulty penetrating the blood-brain barrier. To study this, the 
carbarnate derivative of MD-354 (21), 113, will be synthesized and evaluated in both 
thermal assays. Addition of the carbarnate moiety might sufficiently potentiate the 
lipophilicity of 21 so that it can penetrate the blood-brain barrier. In theory, carbamate 113 
should act as a prodrug and be hydrolyzed to MD-354 (21) in the brain. If 113 does reach 
the supraspinal receptors, then 113 should be hydrolyzed to MD-354 (21) and possess 
antinociceptive activity in the hot-plate assay. Compound 113 will also be evaluated in 
combination with clonidine in both thermal assays and these results will be used to 
compare with the actions of MD-354 (21). If 113 produces a similar dose-response curve 
as MD-354 (21) in the mouse tail-flick assay, this would suggest that 113 is hydrolyzed to 
MD-354 and is interacting in the same manner. 
Next, mechanistic studies will be conducted to determine which pathway, 5-HT3 
and/or ~~~~-adrenoceptor ,  is responsible for potentiation of the clonidine effect. A related 
analog 3,4,5-trichlorophenylguanidine, 29, with a different binding profile will also be 
examined. Compound 29 binds with higher affinity than MD-354 (21) at 5-HT3 receptors 
(Ki = 0.7 nM) but with an affinity similar to that of MD-354 at the azB-adrenoceptors (Ki = 
30 nM). However, unlike MD-354 (21), 29 does not show subtype selectivity (a2*, azc; Ki 
= 32 and 30 nM, respectively). First, 29 will be evaluated in the mouse tail-flick assay. If 
the potentiating effect is due to 5-HT3 receptors, then 29 should be more potent than MD- 
354 in potentiating clonidine (43). Because 29 possesses 50 times the affinity of MD-354 
at 5-HT3 receptors, it should have a comparatively greater potency relative to MD-354 (21) 
in its potentiating effect if the effect is primarily related to a 5-HT3 receptor mechanism. If 
the potentiating effect is via the a2B-adrenoceptors, then 29 should have similar potency as 
MD-354. Antagonist studies also will be conducted to determine the involvement of 5- 
HT3 and/or ~x~~-adrenoceptors. The 5-HT3 antagonist tropisetron (33), the putative a 2 B -  
adrenoceptor antagonist imiloxan (98), and the a2-nonselective adrenoceptor antagonist 
yohimbine (39) will be used to attenuate the potentiating effect of 29. Compound 29 will 
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also be evaluated in the hot-plate assay to see if this compound reaches the supraspinal 
receptors and the results will be compared with those from MD-354 (21). Combination 
studies of 29 and morphine will be conducted to determine if 29 potentiates the 
antinociceptive effects of morphine. Since clonidine (43) has been shown to produce 
i 
sedation via a2-adrenoceptors, 29 will be evaluated in the spontaneous activity assay in 
mice. If 29 produces sedative effects (as indicated by a decrease in locomotor activity), 
then its potentiating effect could possibly be due to induced sedation. If 29 does not 
produce sedation, this would further suggest that it possesses actions which selectively 
potentiate the antinociceptive effect of clonidine (43). 
Another phenylguanidine, 3-methoxyphenylguanidine, 26, will be synthesized and 
examined for possible antinociceptive actions in the mouse tail-flick assay. The rationale 
for its evaluation is that it lacks significant affinity for 5-HT3 receptors (Ki = 1600 n ~ ) , ~ '  
but binds nearly equally well at the three different subpopulations of a2-adrenoceptors 
(a2*, a2J3, a2c; Ki = 177, 152, and 135 nM, respectively). Furthermore, it binds with only 
several-fold lower affinity than 29 at each of the a2-adrenoceptor subtypes. This analog 
will help determine whether 5-HT3 receptors play a significant role in the potentiating 
effect seen with MD-354 (21). A constrained analog of MD-354 (i.e., 114) will also be 
synthesized and examined in antinociceptive assays. The constrained analog of MD-354, 
114, can be used to hrther understand which conformation of MD-354 is more important 
for binding at 5-HT3 and a2~-adrenoceptors. Compound 31 has been previously prepared 
as a conformationally-constrained analog of M D - 3 ~ 4 . ~ ~  Compound 114 represents a 
7 5 
conformationally-constrained rotamer of 31. If it possesses high affinity similar to MD- 
354, then this analog will also be evaluated in both .thermal assays. 
The overall focus of the studies that have been proposed is to determine the 
mechanism of the potentiating effect of clonidine-induced antinociception by MD-354 and 
MD-354-type compounds in the mouse tail-flick assay. 
IV. Results and Discussion 
A. Synthesis 
a) N-(3-Chloropheny1)guanidine Nitrate (MD-354; 21) 
The method of Kreutzberger and   an taw^''^ (Scheme 1) was used to prepare N-(3- 
chloropheny1)guanidine nitrate (21). Cyanamide, 3-chloroaniline (115), and concentrated 
HCl in absolute EtOH were allowed to stir with heating at reflux for 48 h. Thin-layer 
chromatograpy (TLC) was used to monitor the status of the reaction, and after 48 h the 
reaction gave a single separate spot from the starting material. The EtOH was removed 
under reduced pressure and the resulting brown oil was kept at 0 OC overnight. Water and 
an excess of ammonium nitrate were added to give a white precipitate which was collected 
by filtration. The white precipitate was recrystallized from hot water and a drop of MeOH 
to give 21 as a white powder. 
115 21 
Scheme 1. a. NH2CN, EtOH, concentrated HC1, reflux; b. NH4N03, H20. 
b) Carbamate analog of MD-354,113 
Several procedures were used in attempts to synthesize the carbarnate analog of 
MD-354. The procedure of Goetz and zeeh'05 (Scheme 2) was first used. Cyanamide in 
H20,  methyl chloroformate, and 50% NaOH were combined and the pH was maintained 
/ 
between 7 and 8. An exothermic reaction was supposed to increase the temperature to 
between 40 and 45 OC with regulation by cooling. However, the reaction temperature 
barely reached 40 "C and when it did, the temperature dropped quickly. The reaction was 
to be stirred for an additional hour at 50 OC, then freshly distilled aniline 115 was added. 
Concentrated HC1 was added until a pH of about 3 to 3.5 and the reaction mixture was 
heated at reflux for 45 min. However, the reported precipitate did not form, but a sticky 
substance was obtained that was dried under vacuum. The melting point of the unidentified 
Scheme 2. a. H20, 50% NaOH in H20; b. concentrated HC1, reflux 
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crude product (78-80 "C) did not correspond to the literature melting point of 128-129 "C. 
The product of this reaction was never identified. 
The procedure of ~hasanov'" (Scheme 3) was also applied in an attempt to 
synthesize the desired product using calcium cyanamide and methyl chloroformate. The 
_ - - - - - - - - - - - -  
reaction mixture was heated and the temperature was supposed to be maintained between 
40 and 50 "C for 1 h. After 1 h, the reaction mixture was filtered and 3-chloroaniline 
(115) was added to the filtrate. Concentrated HCl was added to the filtrate until the pH 
was adjusted to 3 and the reaction was heated at reflux for 45 min. The desired product 
was reported as a white precipitate, but the product that was collected was an oily residue. 
Although the product was homogeneous to TLC, the 'H NMR spectrum showed that the 
oily residue was not the desired product. The identity of the product was not pursued (but 
- - - - - - - 
see below discussion). 
Scheme 3. a. H20, 40 to 50 "C; b. concentrated HC1, reflux 
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In yet another procedure (Scheme 4), a different approach was used to synthesize 
the carbamate. Methyl chloroformate in dry THF was added to a solution of the free base 
of 21 and triethylamine in dry THF at 0 OC under nitrogen. The reaction mixture was 
allowed to stir at 0 OC for 30 min and then at room temperature for 16 h. After 16 h, the 
precipitate was removed by filtration, and the THF was removed under reduced pressure to 
give a tan powder. The tan powder was recrystallized from hot EtOH, and white crystals 
were collected by filtration. 'H NMR spectral analysis indicated that the product was not 
the desired carbamate, but rather the bis-carbamate analog of MD-354, 116. This 
conclusion was supported by elemental microanalysis. 
21 (free base) 
Scheme 4. a. THF, trie-thylamine, 0 "C, N2,  30 min; b. room temperature, 16 h. 
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Thin-layer chromatographic analysis of the above reaction mixture indicated the 
formation of a second, minor product that was suspected to be the desired product. The 
above procedure was attempted again but the starting material was dissolved in a larger 
amount of THF. It was hoped that this high-dilution technique would minimize formation 
of the bis-carbamate. Under these conditions, TLC analysis showed that there was still a 
small amount of starting material plus two products. The three were separated using 
column chromatography. Carbamate 113 was eventually obtained in low yield as a white 
powder. 
Due to the low yield of the previous reaction, another attempt was made to use the 
procedure of IChasanovlo6 to synthesize the carbamate analog of MD-354 (Scheme 3). By 
using an addition funnel, calcium cyanamide in H 2 0  was added slowly in a dropwise 
manner to methyl chloroformate. The reaction temperature was maintained at around 40 
"C using a hot water bath and was cooled with an ice bath if the temperature exceeded 45 
"C. The reaction mixture was allowed to stir for 20 min and the precipitate was removed 
by filtration; 3-chloroaniline hydrochloride was added to the filtrate. Several drops of 
concentrated HC1 were added to achieve a pH of 3. The reaction mixture was heated at 
reflux for 30 min rather than 45 min. The reaction produced a brown oil which was kept at 
0 "C overnight. The oil obtained was dried under vacuum to yield a solid that was 
recrystallized from hot H 2 0  and a few drops of EtOH. The product was dried using a 
lyophilizer to give 113 as a white powder in low yield. The 'H NMR spectrum of the 
product was consistent for the carbamate hydrochloride. The product isolated from this 
reaction was also consistent with the product from the above reaction as determined by 
8 1 
comparison of 'H NMR spectra. The free base, but not the salt, of 113 has been previously 
reported. 105,106 
c) N-(3-Methoxypheny1)guanidine Nitrate (26). 
The method of Kreutzberger and   an taw^''^ was used to prepare N-(3-methoxypheny1)- 
guanidine nitrate (26) (Scheme 5). Cyanamide, m-anisidine (117), and concentrated HC1 in 
absolute EtOH were allowed to stir while heating at reflux for 24 h. Thin-layer 
chromatograpy was used to monitor the status of the reaction and after 24 h the reaction 
gave a single spot distinct from the starting material. The solvent was removed under 
reduced pressure and half of the resulting brown oil was used to make the salt form of the 
desired product. Water and an excess of ammonium nitrate were added to give a white 
precipitate which was collected by filtration. The white precipitate was recrystallized from 
hot H 2 0  and a drop of MeOH to give 26 as a white powder. 
HN A, NH, HNO, 
I 
Scheme 5. a. NH2CN, EtOH, concentrated HCl, reflux; b NH4N03, H20 
8 2 
d) A conformationally-constrained analog of MD-354, 114 
The method of stadler'07 (Scheme 6) was used to synthesize 114, a constrained 
analog of MD-354 (21). 2-Chloro-6-nitrotoluene (118), N-bromosuccinimide, and benzoyl 
Scheme 6. a. CC14, 250-Watt bulb, reflux; b DMF, reflux; c. HZNNHZ, MeOH, reflux; d. 
Raney Nickel, EtOH, HZ; e. CNBr, EtOH, reflux; f. HBr, ether. 
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peroxide in carbon tetrachloride (CC14) under a 250-Watt light bulb were heated at reflux 
for 26 h. The reaction mixture was filtered and the solvent was removed under reduced 
pressure. TLC analysis showed that there was still a small amount of starting material plus 
one product. The two were sdparated using, column chromatography. The yellow powder 
was collected and recrystallized from EtOH to give 119 as yellow crystals. Compound 119 
and potassium phthalamide in DMF were allowed to stir at room temperature for 2 h. The 
reaction mixture was cooled to room temperature, CHC13 was added and the mixture was 
poured on to H20/ice. The CHC13 portion was washed with 0.2 N NaOH, brine and dried 
with Na2S04. Solvent was removed under reduced pressure to give 120 as yellow crystals. 
Compound 120 and hydrazine hydrate in MeOH were heated at reflux for 3 h. Water was 
added to the reaction mixture and the MeOH then removed under reduced pressure. The 
solution was acidified with concentrated HC1 and heated at reflux for 1 h. The precipitate 
was collected by filtration. A solution of 3 N NaOH was added to the filtrate to maintain a 
pH = 9 and extracted with Et20 and brine. The Et20 extract was dried with Na2S04 and the 
solvent was removed under reduced pressure. TLC analysis showed that there was one 
product and one contaminant. The two were separated using Kugelrohr distillation to give 
121 as a yellow oil. Compound 121 and Raney nickel in EtOH were placed on a Parr 
hydrogenator for 4 h. TLC analysis showed that two products were present. The Raney 
nickel was removed by filtration and washed with MeOH. The filtrates were combined 
and solvent was removed under reduced pressure. The crude product was dissolved in 
Et20, the solution was washed with H 2 0  and brine, and dried with Na2S04. The product 
was converted to its HC1 salt and recrystallized to give 122 HCl as a yellow powder. The 
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free base of 122 and cyanogen bromide in EtOH were heated at reflux for 1 h to provide 
the desired target 114. 
In its protonated form, compound 114 could possibly exist as one of three 
tautomers (Figure 12). That is, any one of the three nitrogen atoms can be protonated. The 
desired product (structure A, Figure 12) is that with the double bond located at the nitrogen 
attached to the phenyl ring. The tautomeric identity of the product was verified by several 
different means. First, the 'H NMR spectrum of the free base of 114 was compared with 
the 'H NMR spectrum of the free base of the product reported in the literature.I0' In the 
literature, it was reported that the NH and NH2 of 114 (free base) gave a broad signal at 4.7 
pprn. However, the 'H NMR spectrum of the free base of 114 prepared here did not show 
Figure 12. Compound 114 can exist as one of three tautomers. 
the signal for the two amines at 4.7 ppm. This difference in 'H NMR spectra could be 
because different 'H NMR spectrometers were used. This could also occur because the 
8 5 
spectrum was run in deuterated DMSO, and if H20 is present in the DMSO the signal for 
the amines can exchange. 
The predicted 'H NMR spectra of the three protonated tautomers (using the 
program ChemDraw) were compared to that of 114. The major difference among the three 
tautomers was that the methylene signal appeared at different shifts. For tautomer A, the 
methylene proton signal is predicted to be at 4.5 ppm whereas for tautomer B it is at 3.91 
ppm, and for tautomer C at 2.6 ppm. This difference helped to determine which of the 
three tautomers was actually obtained. That is, the actual signal for the methylene protons 
of 114 was a singlet at 4.5 ppm. Another source used was the 'H NMR spectrum of a 
similar, previously reported compound, 123.'08 Compound 123 is similar to tautomer A 
except that it does not possess the chloro group on the phenyl ring. When comparing the 
123 
two 'H NMR spectra, the methylene signals are identical and show singlets at exactly 4.5 
ppm. The evidence suggests that 114 is the desired tautomer (i.e., tautomer A as shown in 
Figure 12). 
B. Behavioral Studies 
1. Results 
1.1. MD-354 (21) 
1.1.1. Hot-plate assay 
i 
The antinociceptive activity of MD-354 (21) was compared with that of clonidine 
(43) in the hot-plate assay. When administered via the S.C. route 20 min prior to testing, 2 
mglkg of clonidine produced 80% of the maximal possible effect (MPE, Figure 13). 
Lower doses of clonidine produced less antinociception (Figure 13). In the hot-plate assay, 
Saline 0.25 0.5 1 
Clonidine Dose (mgtkg) 
Figure 13. Antinociceptive actions (f S.E.M.) of subcutaneous clonidine in the hot-plate assay (n 
= 5-8 miceltreatment). Asterisks denote significant differences compared to control group; *P< 
0.001 ; one-way ANOVA followed by Newman-Keuls post hoc test. 
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the potency of clonidine was determined (EDSo = 0.8 mglkg; 95% CL = 0.6-1.1 mglkg). 
For comparison, in the tail-flick assay, EDso = 0.51 mg/kg.lo3 As seen in the tail-flick 
assay, MD-354 failed to produce statistically significant antinociceptive activity in the hot- 
plate assay (Figure 14). MD-354 produced 8-26% MPE at doses of 3, 10, and 30 mgkg 
I 
when administered from 10 to 90 min prior to the test. MD-354 at 30 mglkg produced a 
slight, but not statistically significant time-dependent effect which diminished after the 45- 
min pretreatment time (Figure 14). 
MD-354 Dose (mgtkg): 3 10 10 30 30 30 30 
Time (min): 20 20 45 10 20 45 90 
Figure 14. Effect (f S.E.M.) of subcutaneous MD-354 doses administered 20 to 90 min prior to 
examination in the hot-plate assay (n = 6-16 miceltreatment) as compared to saline control (8 f 2% 
MPE). 
1.1.2. Combination studies 
In the hot-plate assay, MD-354 (21) was evaluated in combination with clonidine. 
Unlike in the tail-flick assay,'03 MD-354 did not potentiate the antinociceptive activity of 
clonidine. Instead, a dose of 30 mglkg of MD-354 (MPE = 11%) slightly antagonized the 
antinociceptive activity of clonidine (doses 0.8 and 2.0 mglkg, 40% and 80% MPE; Figure 
15). However, this slight antagonist effect was not statistically significant. In contrast, a 
Clonidine MD-354 MD-354 Clonidine MD-354 
0.8 mglkg 30 mglkg 30 mg/kg 2 mglkg 30 mglkg 
+Clonidine +Clonidine 
0.8 mg/kg 2 mglkg 
Figure 15. Effect (+ S.E.M.) of subcutaneous MD-354 (30 mglkg) administered in combination 
with clonidine (0.8 and 2.0 m a g ;  s.c.) in the hot-plate assay (n = 5-14 miceltreatment). 
dose of 0.25 mglkg of clonidine (25% MPE) in combination with doses (10 and 30 mglkg, 
10% and 11% W E ,  respectively) of MD-354 slightly elevated the antinociceptive activity 
(NIPE = 33% and 32%, respectively; Figure 16). This slight elevation was not statistically 
significant. 
Clonidine MD-354 MD-354 MD-354 MD-354 
0.25 mglkg 10 mglkg 10 mgkg 30 mglkg 30 mglkg 
+Clonidine +Clonidine 
0.25 mglkg 0.25 mglkg 
Figure 16. Effect (+ S.E.M.) of subcutaneous MD-354 doses administered in combination with 
subcutaneous clonidine (0.25 mglkg) in the hot-plate assay (n = 5-26 miceltreatment). 
1.1.3. MorphineMD-354 combination studies 
Because clonidine has been shown to potentiate the antinociceptive actions of 
morphine (see section I1 C), the effect of a morphine1MD-354 combination was examined. 
Morphine (10 mgkg) produced 95% MPE (Figure 17) when administered via the S.C. route 
30 min prior to the test. The potency of morphine was determined (EDSo = 2 mg/kg; 95% 
CL = 1.2-3.2 mglkg) and found to be consistent with that previously reported in the 
literature.'09 In a combination study, doses of 6, 10, and 30 mglkg of MD-354 did not 
potentiate the antinociceptive activity of 1 mg/kg (29% MPE) of morphine (Figure 18). 
When a dose of 3 mglkg of morphine (66% MPE) was administered in combination with 
MD-354, there was no significant increase in the antinociceptive activity (Figure 19). 
Saline 1 3 5 10 
Morphine Dose (mglkg) 
Figure 17. Antinociceptive actions (k S.E.M.) of subcutaneous morphine in the tail-flick assay (n 
= 5-8 miceltreatment). Asterisks denote significant differences compared to control group; *P< 
0.05, **P<0.01, and ***P<0.001; one-way ANOVA followed by Newman-Keuls post hoc test. 
Morphine 21 Morphine 21 Morphine 21 Morphine 
I mg/kg 6 mglkg 1 mg/kg 10 mglkg 1 mg/kg 30 mg/kg 1 mg/kg 
+ 21 + 21 + 21 
6 mg/kg 10 mdkg 30 mglkg 
Figure 18. Effect (+ S.E.M) of subcutaneous MD-354 (21) doses administered alone and in 
combination with subcutaneous morphine (1 mglkg) in the tail-flick assay (n = 5-11 
miceltreatment). 
Morphine MD-354 MD-354 MD-354 MD-354 
3mglkg 10mg/kg lOmg/kg 30mgIkg 30mgIkg 
+Morphine +Morphine 
3 mg/kg 3 m g k  
Figure 19. Effect (f S.E.M) of subcutaneous MD-354 doses administered alone and in 
combination with subcutaneous morphine (3 mgkg) in the tail-flick assay (n = 5-11 
miceltreatment). 
1.2. N-(3,4,5-Trichlorophenyl)guanidine (29) 
1.2.1. Tail-flick and hot-plate assays 
The antinociceptive activity of 29 was compared with that of MD-354 (21). 
Compound 29 generally produced <30% MPE at doses 0.003, 0.03, 0.3, 1.0, 3.0, 6.0, 10, 
and 30 mglkg when administered 45 min prior to evaluation in the mouse tail-flick assay 
(Figure 20). In the mouse hot-plate assay, 29 produced 4 0  % MPE at doses of 0.3, 1.0, 
and 3.0 mglkg when administered 45 min prior to testing (Figure 21). 
Compound 29 Dose (mg/kg) 
Figure 20. Effect (+ S.E.M.) of subcutaneous compound 29 doses administered 45 min prior to 
examination in the tail-flick assay ( n  = 6-16 rniceltreatment) as compared to saline control (6 f 4% 
MPE). 
Compound 29 Dose (mg/kg) 
Figure 21. Effect (f S.E.M.) of subcutaneous compound 29 doses administered 45 min prior to 
examination in the hot-plate assay ( n  = 6-16 mice/treatment) as compared to saline control (8 f 2% 
MPE). 
1.2.2. Combination studies 
Compound 29 was evaluated in both the tail-flick and hot-plate assays in 
combination with clonidine (43). In the tail-flick assay, a combination of the EDso dose of 
clonidine (0.5 mglkg, MPE = 61%) and an inactive dose of 29 (0.3 mglkg, MPE = 13%) 
1 
potentiated the antinociceptive action of clonidine (MPE = 94%, Figure 22). However, 29 
did not appear to potentiate the antinociceptive action of a very low (i.e., 0.1 mglkg) dose 
of clonidine (Figure 22). But, an inactive dose of clonidine (0.25 mglkg, MPE = 13%) in 
Clonidine 29 29 Clonidine 29 
0.1 mg/kg 0.3 mg/kg 0.3 mg/kg 0.5 mglkg 0.3 mg/kg 
+Clonidine +Clonidine 
0.1 mg/kg 0.5 mg/kg 
Figure 22. Effect (* S.E.M.) of subcutaneous compound 29 (0.3 mg/kg) administered alone and in 
combination with subcutaneous clonidine (0.1 and 0.5 mg/kg) in the tail-flick assay (n = 8 
miceltreatment). Asterisks denote significant differences compared to clonidine control; *P<0.05; 
one-way ANOVA followed by Newman-Keuls post hoc test. 
combination with inactive doses (0.003, 0.03, 0.3, 1.0, 3.0, 6.0, 10, and 30 mgkg) of 29 
produced increases in antinociceptive activity (43-84% MPE; Figure 23). The 
combination of clonidine (0.25 mgkg) and a dose of 0.03 mgkg of 29 (MPE = 4%) gave 
the greatest potentiating effect of the antinociceptive activity of clonidine (MPE = 84%; 
6 
Figure 23). The effect appeared to be biphasic. After an initial increase in antinociception, 
the effect was diminished at 3 mgkg of 29, and was then increased at 10 mgkg of 29 
(Figure 23). 
Clonidine 0.003 0.03 0.3 1 3 6 10 30 
0.25 mgtkg 
Compound 29 Dose (mglkg) 
+ Clonidine 0.25 mgkg 
Figure 23. Potentiation of the antinociceptive actions (f S.E.M.) of subcutaneous clonidine (0.25 
mglkg) by subcutaneous compound 29 in the tail-flick assay (n = 8-9 miceltreatment). Asterisks 
denote significant differences compared to clonidine control; *P<0.05 and **P<0.01; one-way 
ANOVA followed by Newrnan-Keuls post hoc test. 
In the hot-plate assay, a dose of 0.3 mgkg of 29 (MPE = 9%) significantly 
potentiated the effect of the ED5() dose (0.8 mglkg, 40% MPE) of clonidine (combination: 
9 5 
69% MPE, Figure 24). In contrast, a 0.3 mglkg dose of 29 in combination with lower 
doses of clonidine (0.5 and 0.25 mgkg, 38% and 25% MPE; respectively) did not affect 
the antinociceptive effect (MPE = 34% and 15%; Figure 24). 
Clonidine Clonidine Clonidine Clonidine Clonidine Clonidine 
0.25 mg/kg 0.25 mg/kg 0.5 mg/kg 0.5 mglkg 0.8 mg/kg 0.8 mg/kg 
+ 29 + 29 + 29 
0.3 mglkg 0.3 mglkg 0.3 mglkg 
Figure 24. Effect (k S.E.M.) of 29 (0.3 mglkg, s.c.) administered in combination with clonidine 
(0.25, 0.5, and 0.8 mglkg, s.c.) in the hot-plate assay (n = 8-9 mice/treatment). Asterisks denote 
significant differences compared to clonidine control; *P<0.05; one-way ANOVA followed by 
Newman-Keuls post hoc test. 
1.2.3. Mechanistic studies 
An attempt was made to determine the mechanism behind the potentiation of 
clonidine antinociception by MD-354 (21) in the tail-flick assay. Neither imiloxan (98), an 
~ ~ ~ ~ - a d r e n o c e p t o r  antagonist, the 5-HT3 receptor antagonist tropisetron (33), nor yohimbine 
(39), an a2-adrenoceptor antagonist, produced a statistically significant antinociceptive 
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effect in the tail-flick assay when administered alone. Doses of 0.03, 0.1, 0.3, 1.0, and 3.0 
mglkg of imiloxan (98) produced <5% MPE when administered 55 min prior to testing 
(data not shown). Tropisetron (33) produced 4 0 %  MPE at doses 0.0000001, 0.000001, 
0.00001, 0.0001, 0.001, and 0.0035 mgkg when administered 50 min prior to testing (data 
I 
not shown). Yohimbine (39) produced <1% MPE at doses of O.1,0.5, and 1.0 mglkg when 
administered 60 min prior to testing (data not shown). Pretreatment with imiloxan (0.03- 
3.0 mglkg) significantly attenuated the potentiation of clonidine (0.25 mg/kg) by 29 (0.03 
rnglkg) (Figure 25). Interestingly, doses of 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg of imiloxan 
potentiated the antinociceptive actions of clonidine (0.25 mglkg) (Figure 26). 
+ Clonidine 
Imiloxan Dose (mg/kg) 
+ Combination 
Figure 25. Effect (f S.E.M.) of subcutaneous imiloxan on the antinociceptive actions of a 
combination (of subcutaneous clonidine (0.25 mg/kg) and compound 29 (0.03 mg/kg)) in the tail- 
flick assay (n = 8-10 miceltreatment). Asterisks denote significant differences compared to the 
combination control group; *P<O.OS,**P<O.Ol, and ***P<0.001; one-way ANOVA followed by 
Newrnan-Keuls post hoc test. 
Clonidine 0.03 0.1 0.3 1 3 
0.25 mgkg 
  mil ox an Dose (mglkg) 
+ Clonidine 0.25 mglkg 
Figure 26. Potentiation of the antinociceptive actions (f S.E.M.) of subcutaneous clonidine (0.25 
mglkg) by subcutaneous imiloxan in the tail-flick assay (n = 6-1 5 miceltreatment). Asterisks denote 
significant differences compared to control group; *P<0.05; one-way ANOVA followed by 
Newman-Keuls post hoc test. 
Pretreatment with the 5-HT3 antagonist tropisetron (33) (0.00001 and 0.0001 
mglkg) significantly attenuated the increase in the tail-flick latency produced by s.c. 
administration of 29 (0.03 mgkg) in combination with clonidine (0.25 mgkg; Figure 27). 
However, doses of 0.001 to 0.1 mgkg of tropisetron (33) did not significantly attenuate the 
effect of the 29lclonidine combination (Figure 27). Interestingly, doses of 0.0000001, 
0.00000 1, 0.0000 1, 0.000 1, 0.00 1, 0.02, and 0.1 mglkg potentiated the antinociceptive 
actions of clonidine (0.25 mgkg) (Figure 28) although the effects were statistically 
significant only following doses of 0.02 and 0.1 mgkg of tropisetron. Because both 29 
Tropisetron Dose (mglkg) 
+ Combination 
Figure 27. Effect (f S.E.M.) of subcutaneous tropisetron on the antinociceptive actions of a 
combination (of subcutaneous clonidine (0.25 mglkg) and compound 29 (0.03 mgkg)) in the tail- 
flick assay (n = 8-10 miceltreatment). Asterisks denote significant differences compared to the 
combination control group; *P<0.05 and**P<O.Ol; one-way ANOVA followed by Newman-Keuls 
post hoc test. 
and tropisetron (33) potentiate the antinociceptive actions of clonidine, a combination of a 
low, non-potentiating dose of 29 and a low, non-potentiating dose of tropisetron (33) 
should potentiate the action of clonidine. The EDs0 dose for the potentiation of clonidine 
by tropisetron was calculated to be 0.0035 mglkg (calculated using the results from the 
three highest doses shown in Figure 28). Administered with 0.25 mgkg of clonidine, 
0.0035 mgkg of tropisetron (33) produced 51% MPE (Figure 29). In other words, the 
EDso dose for tropisetron (33) did not potentiate the action of clonidine. The half-maximal 
dose for the potentiation of clonidine by 29 (i.e., 0.03 + 2 = 0.015 mgkg) when 
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administered in combination with clonidine also failed to potentiate the antinociceptive 
effect (i.e., 42 L 17 % MPE) (Figure 29). However, a combination of 0.0035 mg/kg of 
tropisetron (33) plus 0.015 mg/kg of 29 in combination with 0.25 mglkg of clonidine 
produced an effect (79 f 12 % MPE; Figure 29) that was stsltistically significant relative to 
the effect of clonidine alone. 
Clonidine lom7 10" lo4 0.001 0.02 0.1 
0.25 mglkg 
Tropisetron Dose (mg/kg) 
+ Clonidine 0.25 mg/kg 
Figure 28. Potentiation of the antinociceptive actions (+ S.E.M.) of subcutaneous clonidine (0.25 
mglkg) by subcutaneous tropisetron in the tail-flick assay (n = 6-8 miceltreatment). Asterisks 
denote significant differences compared to control group; *P<0.05; one-way ANOVA followed by 
Newman-Keuls post hoc test. 
Clonidine Clonidine Clonidine Clonidine Clonidine Clonidine 
0.25 mgkg 0.25 mg/kg 0.25 mgkg 0.25 mg/kg 0.25 mg/kg 0.25 mgkg 
+ 29 + 29 + 33 + 33 + 29 
0.03 mg/kg 0.015 mg/kg 0.1 mgtkg 0.0035 mg/kg 0.015 mg/kg 
+ 33 
0.0035 mgtkg 
Figure 29. Effect (k S.E.M.) of tropisetron (33)(s.c.) and 29 (s.c.) on the antinociceptive actions of 
clonidine (0.25 mgkg; s.c) and 29 (s.c.) in the tail-flick assay (n = 5-7 miceltreatment). Asterisks 
denote significant differences compared to control group; *P<0.01, **P<0.001; one-way ANOVA 
followed by Newman-Keuls post hoc test. Saline produced 6 f 4 % MPE. 
Pretreatment with yohimbine (0.5 and 1 mglkg) significantly attenuated the effect 
observed with the combination of 29 (0.03 mglkg) and clonidine (0.25 mglkg) (Figure 30). 
Doses of 0.1, 0.5, and 1.0 mglkg of yohimbine did not significantly potentiate clonidine 
(Figure 3 1). 
29 0.1 0.5 1 
+Clonidine 
Yohimbine Dose (mglkg) 
+ Combination 
Figure 30. Effect (f S.E.M.) of subcutaneous yohimbine on the antinociceptive actions of a 
combination (of subcutaneous clonidine (0.25 mglkg) and 29 (0.03 mgtkg)) in the tail-flick assay 
(n = 8 miceltreatment). Asterisks denote significant differences compared to control group; 
*P<0.05 and**P<O.Ol; one-way ANOVA followed by Newrnan-Keuls post hoc test. 
Clonidine 0.1 0.5 1 
0.25 mg/kg 
Yohimbine Dose (mgkg) 
+ Clonidine 0.25 mglkg 
Figure 31. Potentiation of the antinociceptive actions (f S.E.M.) of subcutaneous clonidine (0.25 
mglkg) by subcutaneous yohimbine in the tail-flick assay (n = 8-16 miceltreatment). 
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In the tail-flick assay, 2.0 mglkg of morphine produced 39% MPE (Figure 32), 
which was similar with that previously reported in the literature.'09 In a combination study, 
doses of 0.003, 0.03, and 1.0 mglkg of 29 slightly potentiated the antinociceptive activity 
of 2.0 mglkg of morphine (Figure 32). The observed effect was not statistically 
significant. However, a combination of 2 mg/kg of morphine plus 10 mg/kg of 29 
significantly decreased the antinociceptive activity of morphine. 
Morphine 0.003 0.03 0.1 1 3 10 
2 m g / k  
Compound 29 Dose (mg/kg) 
+ Morphine 2 mgkg 
Figure 32. Effect (f S.E.M.) of subcutaneous compound 29 doses administered in combination 
with morphine (2 mglkg, s.c.) in the tail-flick assay (n = 6-8 miceltreatment). Asterisks denote 
significant differences compared to control group; *P<0.05; one-way ANOVA followed by 
Newman-Keuls post hoc test. 
1.2.4. Spontaneous activity 
Subcutaneous administration of 0.03 mglkg of 29 after 15, 30, and 45 min 
produced saline-like effects in three main measures of locomotor activity. For example, 
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after 45 min the measure of (i) total movements was recorded as 350 f 24 and 322 f 28 for 
saline and 29, respectively; (ii) total movement time in seconds was 1472 + 143 for saline 
and 141 1 f 165 for 29; (iii) total movement distance in centimeters was 5 175 f 919 and 
4470 + 625 for saline and 29, respectively. Subcutaneous administration of 29 (0.03 
mglkg) in combination with subcutaneous clonidine (0.25 mglkg) after 15, 30, and 45 min 
produced clonidine-like effects in three main measures of activity. After 45 min the 
measure of (i) total movements were recorded as 123 f 22 and 164 f 154 for clonidine and 
29 + clonidine, respectively; (ii) total movement time in seconds was 404 5 76 for 
clonidine and 632 f 154 for 29 + clonidine; (iii) total movement distance in centimeters 
was 1287 f 272 and 2039 + 480 for clonidine and 29 + clonidine, respectively. 
1.3. The carbamate analog of MD-354,113 
1.3.1. Tail-flick assay 
The antinociceptive properties of the carbamate analog of MD-354 (21), 113, were 
compared with those of MD-354. Compound 113 failed to produce a statistically 
significant antinociceptive effect when administered alone (Figure 33). Compound 113 
produced <5% MPE at doses 0.3, 1 .O, 6.0, and 10 mglkg when administered 45 min prior 
to testing (Figure 33). To determine an optimal pretreatment time, selected 113 doses were 
examined using various pretreatment times (in addition to the 45-min pretreatment time) 
but did not produce >lo% MPE (data shown in Figure 34 for 1 mglkg of 113). 
Compound 113 Dose (mgtkg) 
Figure 33. Effect (f S.E.M.) of 113 doses administered s.c. 45 min prior to examination in the 
tail-flick assay (n = 6-8 rniceltreatment) as compared to saline control (6 f 4% MPE). Note scale 
of y axis. 
20 min 45 min 90 min 120 min 
Compound 113 Dose (1.0 mgtkg) 
Figure 34. Effect (f S.E.M.) of a 113 dose (1 mglkg, s.c.) administered 5 to 120 min prior to 
examination in the tail-flick assay (n = 6-8 rniceltreatment) as compared to saline control (6 If: 4% 
MPE). Note scale of y axis. 
1.3.2. Combination studies 
In the tail-flick assay, doses of 0.3, 1.0, 3.0, 6.0, and 10 mgkg of 113 potentiated 
the antinociceptive actions of clonidine, when tested 45 min after administration (Figure 
35), but the effect was statistically significant only after the 1.0 and 10 mglkg doses. To 
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determine the optimal pretreatment time, a dose of 1.0 mglkg of 113 with clonidine (0.25 
mglkg) was examined using various pretreatment times (in addition to the 45 min 
pretreatment time). The 113lclonidine combination was most effective following a 11 3 
pretreatment time of 5 to 90 min (Figure 36). 
Clonidine 0.3 1 3 6 10 
0.25 mg/kg 
Compound 113 Dose (mg/kg) 
+ Clonidine 0.25 mgtkg 
Figure 35. Potentiation of the antinociceptive actions (f S.E.M.) of clonidine (0.25 mglkg, s.c.) by 
subcutaneous 113 in the tail-flick assay (n = 7-9 miceltreatment) 45 min post administration of 
compound 113. Asterisks denote significant differences compared to control group; *P<0.05; one- 
way ANOVA followed by Newman-Keuls post hoc test. 
Clonidine 5 min 20 min 45 min 90 min 120 rnin 
0.25 mglkg 
Compound 113 Dose (1.0 mg/kg) 
+ Clonidine 0.25 mgkg 
Figure 36. Potentiation of the antinociceptive actions (f S.E.M.) of clonidine (0.25 mgkg, s.c.) by 
113 (1.0 mglkg, s.c.) when administered 5 to 120 min prior to examination in the tail-flick assay (n 
= 8-9 miceltreatment). Asterisks denote significant differences compared to control group; 
*P<0.05; one-way ANOVA followed by Newman-Keuls post hoc test. 
1.4. N-(3-Methoxypheny1)guanidine (26) 
1.4.1. Tail-flick assay 
The antinociceptive actions of the methoxy counterpart of MD-354, 26, were 
compared with those of MD-354. N-(3-Methoxypheny1)guanidine failed to produce a 
significant antinociceptive effect when administered alone (Figure 37). Compound 26 
produced <lo% MPE at doses 0.03,0.3, 1.0,3.0,6.0, 10, and 30 mglkg when administered 
45 rnin prior to testing. 
1 3 6 10 30 
Compound 26 Dose (mglkg) 
Figure 37. Effect (f S.E.M.) of subcutaneous 26 doses administered 45 rnin prior to examination 
in the tail-flick assay (n = 5-7 miceltreatment) as compared to saline control (6 f 4% MPE). Note 
scale of y axis. 
1.4.2. Combination studies 
In the tail-flick assay, a combination of the ED5() dose of clonidine (0.5 mglkg) plus 
inactive doses of 26 (0.03, 0.3, 1.0, 3.0, 6.0, 10, and 30 mgkg) potentiated the 
antinociceptive effect in mice (MPE = 50-100%; Figure 38) but this increase was not 
statistically significant except at doses of 0.3 and 6 mgkg of 26. A lower dose of 
clonidine (0.25 mglkg) in combination with doses (0.3, 1.0, and 10 mglkg) of 26 did not 
result in statistically significant potentiation of the antinociceptive effect (3 1-47% MPE; 
Figure 39). 
Clonidine 0.03 0.3 1 3 6 10 30 
0.5 mg/kg 
Compound 26 Dose (mgkg) 
+ Clonidine 0.5 mglkg 
Figure 38. Potentiation (f S.E.M.) of the antinociceptive actions of clonidine (0.5 mgtkg, s.c.) by 
subcutaneous 26 in the tail-flick assay (n = 7 rniceltreatment). Asterisks denote significant 
differences compared to control group; *P<0.05; one-way ANOVA followed by Newrnan-Keuls 
post hoc test. 
Clonidine 0.3 1 10 
0.25 mg/kg 
Compound 26 Dose (mgkg) 
+ Clonidine 0.25 mglkg 
Figure 39. Effect (+ S.E.M.) of subcutaneous 26 doses administered in combination with 
clonidine (0.25 mgkg, s.c.) in the tail-flick assay (n = 7 miceltreatment). 
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2. Discussion 
MD-354 (21) binds selectively both to 5-HT3 receptors and a2~-adrenoceptors, and 
since both receptor populations have been implicated as playing a role in nociception, the 
antinociceptive actions of MD-354 were evaluated. It was previously shown in our 
laboratory that MD-354 is inactive in the mouse tail-flick assay (Figure 10). Interestingly, 
MD-354 potentiated the antinociceptive actions of an inactive dose of clonidine (Figure 
1 1). Based on these results, the purpose of the present study was to examine MD-354 in a 
different pain model, and to investigate its potential mechanism(s) of action accounting for 
its potentiating effect on clonidine analgesia. One of the first studies conducted was to 
determine whether MD-354 (21) is active in a different thermal pain test (i.e., hot-plate 
assay). Clonidine was used as a positive control and evaluated in the hot-plate assay (ED5' 
= 0.8 mglkg). The results obtained (Figure 13) were consistent with those reported in the 
literature.''' Subsequently, MD-354 was evaluated in the mouse hot-plate assay. As in the 
tail-flick assay, MD-354 did not produce any antinociceptive activity (Figure 14). 
However, unlike what was seen in the tail-flick assay, MD-354 did not potentiate the 
antinociceptive activity of clonidine in the mouse hot-plate assay (Figures 15 and 16). 
There are several possible explanations for these differences. The tail-flick assay might 
involve different receptor subpopulations or a different receptor mechanism than the hot- 
plate assay. For instance, the tail-flick assay involves spinal receptors,95 whereas the hot- 
plate assay involves supraspinal receptors.98 It has been suggested that supraspinal 5-HT3 
receptors might not be involved with spinal analgesia.4' This was supported by a study 
showing that the nonselective 5-HT3 receptor agonist, 2-methyl-5-HT did not produce 
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antinociception when administered directly into the brain.4' Therefore, if supraspinal 5- 
HT3 receptors are not involved with nociception, then any possible antinociceptive activity 
observed with the arylguanidines in the hot-plate assay would primarily involve non-5-HT3 
supraspinal receptors. Another possibility could be that there is a low density of a2B- 
adrenoceptors present in the brain, and/or that MD-354 may not reach these receptors. 
Since there is only a small number of supraspinal a2~-adrenoceptors61-63 and supraspinal 5- 
HT3 receptors,41 these might not be involved in nociception; this could possibly explain 
why MD-354 does not potentiate clonidine in the mouse hot-plate assay. Differences 
might also be related to the fact that MD-354 is not a very lipophilic agent and 
distributional factors could be involved. MD-354 has an experimentally determined Log P 
value of - 0 . 6 4 , ~ ~  indicating that it might have difficulty penetrating the blood-brain barrier. 
The carbamate derivative of MD-354, 113, was synthesized and examined to study 
this factor. In theory, the more lipophilic 113 should more readily penetrate the blood- 
brain barrier than MD-354 (21), and be subsequently hydrolyzed by brain tissue esterases 
to MD-354. Compound 113 produced an effect similar to that of MD-354. As reported for 
MD-354,Io3 compound 113 (doses of 0.3 to 10 mglkg) did not produce antinociceptive 
effects when administered 5 to 120 min prior to testing in the mouse tail-flick assay 
(Figures 33 and 34). This suggests that 113 might be rapidly hydrolyzed shortly after 
administration. When administered in combination with clonidine (0.25 mglkg), however, 
113 potentiated the antinociceptive actions of clonidine (Figure 35) much in the same 
manner as did MD-354. Previously we have shown that MD-354 potentiates the 
antinociceptive effect of clonidine in a bell-shaped manner (Figure 1 1).'03 Re-examination 
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of 1 mglkg of MD-354 (MPE = 1%) in combination with clonidine (0.25 mglkg; MPE = 
13%) resulted in a supraadditive (statistically significant) antinociceptive effect (MPE = 
84%; data not shown). Furthermore, these new data clearly indicate that a potentiation of 
antinociceptive actions of clonidine by MD-354 occurs in a biphasic manner; this was also 
seen for its carbamate analog 113. Overall, these results suggest that 113 may be 
hydrolyzed to MD-354 in the periphery and behaves in the same manner as MD-354. The 
potentiating effect of clonidine with 113 was also examined at various pretreatment 
intervals (5 to 120 min) before the test (Figure 36). This might give an idea of how fast 
113 is hydrolyzed in vivo and how long the observed potentiating effect lasts. When 113 
was administered 15 min after clonidine and 5 min before the test, the effect was similar to 
when 113 was administered 45 min before the test (Figure 36). Although, the results 
suggest that 113 is probably hydrolyzed within at least 5 min of administration, the 
potentiating effect lasts up to 120 min, even though at 120 min the 113lclonidine 
combination produced a lower %MPE. Further studies will be required to examine the rate 
of hydrolysis of 113 in vivo. In any event, 113 seems to behave much like its parent: MD- 
354. It would seem that the carbamate is too rapidly hydrolyzed to show effects 
substantially different than those seen with MD-354. Therefore 113 was not examined in 
the mouse hot-plate assay. The concept, however, is still a valid one. Future studies might 
target carbamate analogs with bulkier substituents that are not as rapidly hydrolyzed as 
113. 
Next, mechanistic studies were conducted to help determine which pathway, 5-HT3 
andlor a2B-adrenoceptors, is responsible for the potentiation of clonidine analgesia by 
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arylguanidines. Some of these studies utilized structurally modified arylguanidines 
whereas other studies utilized 5-HT3 and adrenoceptor antagonists. In order to h l ly  
understand which pathway is involved, several analogs of MD-354 (21) with different 
binding profiles from MD-354 were studied. The first approach was to determine the 
importance of 5-HT3 receptors in the potentiation of the antinociceptive actions of 
clonidine by arylguanidines. A MD-354-related analog, 29, with a different binding 
profile was examined. Compound 29 binds with about 50-fold higher affinity than MD- 
354 at 5-HT3 receptors, and with similar affinity at a2B-adrenoceptors. However, unlike 
MD-354, 29 does not show subtype selectivity for a2-adrenoceptors (Table 10). 
Compound 29 alone did not produce an analgesic effect when administered 45 min before 
the test in the tail-flick assay (Figure 20). When administered in combination with 
clonidine, 29 (0.3 mg/kg) potentiated the antinociceptive actions of clonidine (Figure 23) 
and was about as effective as 1 mg/kg of MD-354. A much lower dose of 29 (0.03 mg/kg) 
still produced potentiation of the clonidine effect. That is, 29 is at least 33 times more 
potent than MD-354 in potentiating the antinociceptive actions of clonidine. Since 29 is 50 
times more potent than MD-354 in binding at 5-HT3 receptors, this might explain the 
comparatively greater potency of 29 relative to MD-354 in potentiating clonidine's 
antinociceptive actions. In theory, if the potentiating effect of clonidine by MD-354 
primarily involves 5-HT3 receptors then 29 should be more potent than MD-354 in 
potentiating clonidine. If a2B-adrenoceptors primarily mediated the potentiating effect of 
Table 10. Binding Data for MD-354 (21), 29, and 26 at 5-HT3 and a2-Adrenoceptors. 103,l 1 1  
Ki (nM) 
Adrenocevtors 
clonidine, then 29 should have a similar potency relative to MD-354. Because 29 is more 
potent in potentiating clonidine than MD-354, this further suggests that 5-HT3 receptors 
may be involved in the potentiation of clonidine by arylguanidines. However, the 
involvement of a2-adrenoceptors cannot be ruled out. Compound 29 also has a higher 
affinity for a2,4- and a2c-adrenoceptor subtypes than MD-354 (Table 10). Compound 29 is 
about 25 times more potent than MD-354 in binding at a2A-adrenoceptors and 5 times 
more potent in binding at a2c-adrenoceptors. Since it has been shown that the a2,4- 
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adrenoceptor subtype plays a role in antinociception, the increase in potency might also 
involve the activation of a2A-adrenoceptors. It might also be noted that 29 is more 
lipophilic than MD-354 ( 2 1 ) ; ~ ~  hence, 29 might be more potent than MD-354 because 
more of it reaches supraspinal sites. Compound 29 was also studied in the mouse hot-plate 
I 
assay. The results were similar to that of MD-354, when 29 (0.3 mglkg) was administered 
in combination with doses of 0.25 and 0.5 mglkg of clonidine, in that 29 did not potentiate 
the antinociceptive activity of clonidine. Interestingly, 29 significantly potentiated the 
antinociceptive activity of the EDs0 dose of clonidine (0.8 mglkg) in the mouse hot-plate 
assay (Figure 24). These results suggest that 29 could be liphophilic enough to cross the 
blood-brain barrier and reach supraspinal sites. Compound 29 possesses higher affinity for 
5-HT3 receptors, a 2 ~ -  and a2c-adrenoceptors than MD-354 and this could also explain the 
potentiation of clonidine in the mouse hot-plate assay 
Another phenylguanidine, 26, was examined for possible antinociceptive actions in 
the tail-flick assay. Compound 26 lacks significant affinity for 5-HT3 receptors but binds 
nearly equally well at the three different subpopulations of a2-adrenoceptors (Table 10). 
Furthermore, it binds with only several-fold lower affinity than 29 at each of the 
adrenoceptor subtypes. Compound 26 did not produce antinociception when administered 
alone (Figure 37). Interestingly, 26 did not potentiate the antinociceptive actions of an 
inactive dose of clonidine (0.25 mglkg) (Figure 39). The lack of potentiating effect of 26 
on the antinociceptive action of clonidine can be directly attributed to its low affinity for 5- 
HT3 receptors. Methoxy-compound 26 binds with 46-fold and >2,000 fold lower affinity 
than MD-354 (21) and 29, respectively. Its reduced ~t~~-adrenoceptor affinity might also 
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play a role here. Interestingly, 26 (at doses 0.3 and 6.0 mglkg) potentiated the 
antinociceptive activity of the EDso dose of clonidine (0.5 mglkg) (Figure 38). 
In the antagonist studies conducted, the potentiating effect of 29 in combination 
with clonidine was significantly antagonized by the 5-HT3 antagonist tropisetron (doses 
0.0000 1 and 0.000 1 mglkg), the a2~-adrenoceptor antagonist imiloxan (doses 0.03 to 3.0 
mglkg), and the nonselective a2-adrenoceptor antagonist yohimbine (doses 0.5 and 1.0 
mglkg). The non-selective a2-adrenoceptor antagonist yohimbine completely abolished 
the potentiating effect of 29 on clonidine (Figure 30). This observation is fairly simple to 
explain. Because clonidine is believed to produce its antinociceptive effects via an a2-  
adrenoceptor rnechani~rn,~ unavailability of a2-adrenoceptors (by yohimbine blockade) 
would be expected to result in inactivity. Clonidine, alone or in combination with an 
inactive arylguanidine, would not be expected to show any antinociceptive effect in the 
presence of yohimbine. 
The effect of clonidine (or clonidinelarylguanidine combinations) with tropisetron 
or imiloxan is more complex, and might be dose related. Results with tropisetron and 
imiloxan support the concept that the potentiation of clonidine by arylguanidines might 
involve both 5-HT3 and a2B-adrenoceptors. The a2B/a2c-adrenoceptor antagonist imiloxan 
failed to block the potentiating effect of MD-354 (21) on clonidine a n t i n o c i ~ e ~ t i o n . ' ~ ~  
However, imiloxan was shown to potently antagonize the potentiating effect of 29 (Figure 
25). The different results will require additional study, but they certainly suggest 
involvement of a2Bla2c-adrenoceptors in the action of 29. However at doses of 0.3 and 3.0 
1 I6 
mglkg, imiloxan (98), in the absence of 29, potentiated the antinociceptive activity of 
clonidine (0.25 mglkg). The potentiating effect of clonidine by imiloxan might be 
explained by several possibilities. Clonidine binds nonselectively at the three a2-  
adrenoceptor subtypes. It has been shown that both (2.2~- and a2B-adrenoceptor subtypes 
I 
are involved with a n t i n o c i ~ e ~ t i o n . ~ ~ ~ ~  When given in combination with clonidine, imiloxan 
could bind to a2B/2c-adrenoceptors and prevent clonidine from binding at these receptors. 
This would allow clonidine to bind at more spinal and supraspinal ~t~~-adrenoceptors than 
before and could possibly potentiate its antinociceptive actions. Also, a2A-adrenoceptors 
mediate the sedative effects caused by ~lonidine. '~ Therefore, if more a2A-adrenoceptors 
are being activated then this could possibly potentiate the sedative effect as well. An 
increase in sedation might be mistaken for an increase in antinociceptive properties. There 
are several approaches that could be used to determine if sedative effects are involved in 
the enhancing effect of clonidine antinociception by imiloxan. One approach is to examine 
imiloxan in combination with clonidine in the locomotor activity assay. If imiloxan does 
not potentiate the locomotor effects of clonidine, then this could suggest that sedative 
effects are not responsible for the enhancing effect of clonidine's antinociceptive action by 
imiloxan. Another approach is to try to block the greater than additive effect of imiloxan 
and clonidine with an a2~-adrenoceptor antagonist (e.g. BRL 44408). 
Evidence was obtained that 5-HT3 receptors also play a role. That is, the 5-HT3 
antagonist tropisetron was able to block the potentiation of clonidine antinociception by 29 
(Figure 27). Interestingly, however, administration of tropisetron potentiated the 
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antinociceptive effects of clonidine in the absence of 29 (Figure 28). It might be argued 
that 29, at least in part, potentiates the effect of clonidine by a 5-HT3 agonist mechanism; 
this is consistent with the observation that the effect of clonidinel29 is blocked by the 5- 
HT3 antagonist tropisetron. It is much more difficult to reconcile the observation that 
tropisetron by itself potentiates the action of clonidine. Overall, the results imply that 5- 
HT3 antagonists are capable of potentiating the antinociceptive actions of clonidine. 
Evidently, this is more complex than it would first seem to be. Taken together, the results 
of the present investigation suggest that arylguanidines potentiate the antinociceptive 
actions of clonidine via both an a2-adrenoceptor and 5-HT3 receptor mechanism. Although 
the arylguanidines might behave as a2-adrenoceptor agonists (or partial agonists), the 
specific a2-adrenoceptor subtype(s) involved remains to be elucidated. Several of the 
studies argue in favor of a role for 5-HT3 receptors; but here, it is unclear whether the 
agents act via a 5-HT3 agonist or antagonist (or both) mechanism. 
Surprisingly, at doses 0.02 and 0.1 mglkg, tropisetron potentiated the 
antinociceptive actions of clonidine. These results further suggest that the mechanism of 
antinociception via 5-HT3 and a2-adrenoceptors are interrelated. It has been shown that 
the combination of 5-HT (1) and norepinephrine (36) produces a synergistic effect on 
a n t i n o c i ~ e ~ t i o n . ~ . ~ ~  Because tropisetron is both a 5-HT3 and 5-HT4 antagonist, another 
explanation is that tropisetron is blocking both 5-HT3 and 5-HT4 receptors and the 
antagonist activity at one or both of these serotonin receptors could influence levels of 5- 
HT. The available 5-HT could mediate the release (e.g. via heteroreceptors) of other 
neurotransmitters which activate their corresponding descending inhibitory systems (e.g. 
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NE, G A B A ) . ~ , ' ~  Serotonin, by interacting with 5-HT3 receptors, can also modulate the 
release of other neurotransmitters and neuropeptides (i.e., dopamine, acetylcholine, 
GABA, substance P, ch~lec~stokinin) .~ '  Another possibility could be that %-adrenoceptor 
antagonists block the antinociception mediated by 5-HT3 receptors because the two 
systems are functionally related. 
The effect of the EDso dose of the potentiating dose of tropisetron (33) and half of 
the potentiating dose of 29 in combination with clonidine (43) was studied. In theory 
because both tropisetron and 29 potentiate clonidine when administered alone, the low 
doses of tropisetron and 29 together should potentiate clonidine in a similar manner. An 
EDso dose of 0.0035 mglkg of tropisetron and half the active dose of 29 (0.015 mglkg) 
potentiated the antinociceptive actions of clonidine in a similar manner as the 29lclonidine 
combination. These results suggest that 29 is potentiating clonidine in the same manner as 
tropisetron (i.e., via a 5-HT3 receptor antagonist mechanism). These findings of tropisetron 
and 29 potentiating clonidine could be used clinically. Since tropisetron is already being 
used as an antiemetic, using tropisetron with clonidine, or using the three agents (i.e., 
tropisetron, clonidine, and an arylguanidine) in combination could be clinically useful in 
the treatment of pain associated with cancer. 
The results with 5-HT3 and/or azB-adrenoceptor antagonists show that the 
potentiating effect of 29 with clonidine might involve a biphasic mechanism. This means 
that at extremely low doses, 5-HT3 receptors might be involved and that at higher doses, 
azB-adrenoceptors could be involved in the action of.29. It might be noted that 5-HT3 
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receptor ligands commonly show potent actions (i.e., at sub-mglkg doses) in a variety of 
pharmacological assays.42 
Clonidine (43), a nonselective a2-adrenoceptor agonist, potentiates the 
antinociceptive actions of morphine but the exact adrenooeptor population responsible is 
still unknown.90 Since the potentiation of clonidine by 29 might involve a2-adrenoceptors 
via an agonist mechanism, 29 was also examined in combination with morphine in the tail- 
flick assay. In theory, if the potentiating effect of 29 involves a2-adrenoceptors as with 
clonidine, then 29 should potentiate the antinociceptive actions of morphine. Compound 
29 potentiated the antinociceptive effect of morphine (2 mg/kg) (Figure 32) only at doses 
of 0.003, 0.03, and 1 mglkg of 29 but the effect was not statistically significant. In 
contrast, doses of 0.1 and 3 mglkg of 29 slightly attenuated the antinociceptive action of 
morphine (2 mg/kg); but here, too, the effect was not statistically significant. However a 
dose of 10 mglkg of 29 blocked the actions of morphine and these results were statistically 
significant (Figure 32). The studies of 29 in combination with morphine can be explained 
in several ways. As mentioned earlier, co-administration of a2-adrenoceptor agonists and 
opioid agonists produce a synergistic effect.90 These results suggest that certain doses of 29 
possibly potentiate morphine's antinociception via an a*-adrenoceptor agonist mechanism. 
Earlier studies also showed that i.t. or i.c.v. administered morphine produces 
antinociception that can be blocked by the 5-HT3 antagonist t r ~ ~ i s e t r o n . ~ ~  Consequently, 
any adrenergically-mediated potentiating effects of 29 might be counteracted by the 
antagonist actions of 29 at 5-HT3 receptors if 29 is a 5-HT3 partial agonist. These results 
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from the 29lmorphine studies suggest that 29 could be a 5-HT3 antagonist and an a*- 
adrenoceptor agonist. 
In the studies of MD-354 in combination with morphine, MD-354 (at doses 6 and 
10 mglkg) did not seem to affect the antinociceptive action of morphine (1 mglkg) (Figure 
18). However, a dose of 30 mglkg of MD-354 (21) attenuated morphine antinociception 
but these results were not statistically significant. This difference in activity seen with 
MD-354 and 29 might be explained by the compounds' different binding profiles. Since it 
was proposed earlier that the attenuation seen with 29 might involve a 5-HT3 receptor 
antagonist mechanism, the difference in activity could be due to the fact that 29 binds with 
a 50-fold higher affinity at 5-HT3 receptors than MD-354 (Table 10). Also, different doses 
were used in the two studies of MD-354 or 29 in combination with morphine. These 
different doses could also explain the difference in activity with these two arylguanidines. 
MD-354 was studied in combination with a lower dose of morphine (1.0 mglkg) than 29, 
whereas 29 was studied with the EDso dose of morphine (2.0 mglkg). This difference 
suggests that the higher dose of morphine (2.0 mglkg) could possibly require a lower dose 
of 29 (1 0 mglkg) to block its antinociceptive actions. In the case of MD-354, using a dose 
of 1.0 mglkg of morphine might require a higher dose of 30 mglkg of MD-354 to block its 
antinociceptive actions. Further studies are needed to hl ly explain the difference in 
activity seen with MD-354 and 29 in combination with morphine. 
Clonidine has been shown to produce sedation through activation of a 2 -  
adrenoceptors. h order to determine whether the potentiating effect by 29 is caused by 
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antinociceptive effects or sedation, 29 was studied in a locomotor activity assay. 
Compound 29 did not produce sedation in mice; this further suggests that 29 produces its 
potentiating effect via an antinociceptive action and not a sedative effect. The combination 
of 29 with clonidine was also studied and compared with the results of clonidine by itself. 
The purpose of studying the combination was to see if 29 only potentiates clonidine's 
antinociceptive actions or whether it also potentiates clonidine's sedative effects. The 
combination of 29 and clonidine produced clonidine-like effects in the locomotor activity 
assay and suggests that 29 selectively potentiates the antinociceptive, but not sedative 
effects of clonidine. This finding could be beneficial if 29 was clinically used in 
combination with clonidine because sedation caused by clonidine is an undesired side 
effect. 
V. Conclusions 
In summary, MD-354 is a rather selective 5-HT3/a2B-adrenoceptor ligand. 
However, MD-354 was found to lack antinociceptive action by itself in the mouse tail-flick 
assay,Io3 and in the mouse hot-plate assay (present study). Although MD-354 potentiated 
the antinociceptive effect of clonidine in the tail-flick assay, it did not potentiate the action 
of clonidine in the hot-plate assay. These differences might reflect roles for spinal versus 
supraspinal loci of action. Compound 113, a carbamate derivative of MD-354, produced a 
similar biphasic dose-response curve as MD-354. This study suggests that 113 is rapidly 
hydrolyzed in vivo to MD-354. Compound 29, which binds at 5-HT3 receptors with 50 
times the affinity of MD-354, was extremely potent in potentiating the antinociceptive 
effects of clonidine and was about 30 times more potent than MD-354. The potentiation of 
clonidine by 29 can be blocked by the 5-HT3 receptor antagonist tropisetron, the a2~- 
adrenoceptor antagonist imiloxan, and the a*-adrenoceptor antagonist yohimbine. This 
shows that both 5-HT3 and a2-adrenoceptors are involved in the potentiation of clonidine 
antinociception by 29. Compound 26, an analog of MD-354 that lacks affinity at 5-HT3 
receptors, did not potentiate the effect of an inactive dose of clonidine in the tail-flick 
assay. However, 26 potentiated the effect of the EDso dose of clonidine (0.5 mglkg); 
however, this potentiation was statistically significant only at doses of 0.3 and 6.0 mglkg. 
The mechanism underlying clonidine potentiation requires further investigation; 
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nevertheless a role for 5-HT3 and a*-adrenoceptors has been established. At least some 
arylguanidines might be referred to as "dual-mechanism" potentiating agents of the 
antinociceptive actions of clonidine. Another major finding of the present investigation is 
that the 5-HT3 antagonist tropisetron, which is currently being used as an antiemetic agent 
in cancer chemotherapy, can potentiate the analgesic effect of clonidine. Consequently, 
clinicians should consider investigating combinations of these two clinically employed 
agents to control the pain associated with certain types of cancer. 
VI. Experimental 
A. Synthesis 
Melting points were determined in a glass capillary on a Thomas Hoover melting 
point apparatus and are uncorrected. Proton nuclear magnetic resonance ( 'H NMR) 
spectra were obtained on a Varian Gemini 300 MHz spectrometer and peak positions are 
given in parts per million (6) downfield from TMS. Elemental analysis was performed by 
Atlantic Microlab Inc. (Norcross, GA), and determined values are within 0.4% of theory. 
Column chromatography was performed on silica gel (Kiesel gel 40, 0.040-0.063 mm, 
Merck) by flash chromatography. Routine thin-layer chromatography (TLC) was 
performed on silica gel GHLF plates (250 p, 2.5 x 10 cm; Analtech Inc., Newark, DE). 
Infrared spectra were obtained on a Nicolet Avatar 360 FT-IR spectrometer. 
N-(3-Chloropheny1)guanidine Nitrate (MD-354) (21). Cyanamide (1.05 g, 33.7 mmol) 
was added to a solution of 3-chloroaniline (115) (2.00 g, 15.7 mmol) and concentrated HC1 
(1.60 mL) in absolute EtOH (15 mL). The stirred mixture was heated at reflux for 48 h. 
The solvent was removed under reduced pressure and the resulting oil was cooled at 0 OC. 
Water (15 mL) and ammonium nitrate (3.0 g) were added to give a precipitate which was 
collected by filtration and recrystallized from H 2 0  and MeOH to give 21 (1.50 g, 41%) as 
a white powder: mp 169-1 70 OC (lit.Io4 mp 171-172 OC); 'H NMR (DMSO-d6) 6 7.32-7.36 
(m, 4H, NH), 7.40-7.50 (m, 4H, ArH), 9.80 (s, 1 H, H'NH). 
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N-(3-Methoxypheny1)guanidine Nitrate (26). Cyanamide (0.60 g, 15 mmol) was added 
to a solution of m-anisidine (117) (1.20 g, 10 mmol) and concentrated HCl (0.8 mL) in 
absolute EtOH (10 mL). The stirred reaction mixture was heated at reflux for 24 h. The 
solvent was removed under reduced pressure and the resulting oil was cooled to 0 OC. 
Water (5 mL) and ammonium nitrate (0.73 g) were added to give a precipitate which was 
collected by filtration and recrystallized from H20  and MeOH to give 26 (0.10 g, 19%) as 
a white powder: mp 139-141 OC; I H  NMR (DMSO-d6) 6 3.76 ( s, 3H, 0CH3), 6.80-6.88 
(m, 3H, Ar-H), 7.31-7.37 (t, lH, ArH), 7.52-7.56 (m, 4H, NH), 9.85 (s, lH, 'NH). Anal. 
Calcd for (CsHI 1N30 HN03) C,H,N. 
Methyl N-(3-chlorophenyl)guanidinecarboxylate Hydrochloride (113). Method A. 
Methyl chloroformate (0.17 mL, 2.15 mmol) in dry THF (2 mL) was added in a dropwise 
manner to a solution of the fiee base of (3-chloropheny1)guanidine (21) (0.50 g, 2.15 
mmol) and Et3N (0.60 mL, 4.30 mmol) in dry THF (100 mL) at 0 OC under an N2 
atmosphere. The mixture was allowed to stir at 0 OC for 30 min and then at room 
temperature for 16 h. The white precipitate was removed by filtration and the solvent was 
removed under reduced pressure to give a mixture of two products which were separated 
by column chromatography (silica gel, Kiesel gel 40, 0.040-0.063 mm) using CH2C12 1 
MeOH (4: 1) as eluent. The free base of the desired product (113) was recrystallized from 
EtOH to give 0.01 g (2%) of a white powder: mp 128-129 "C (lit.Io6mp 138-140 OC); 'H 
NMR (CDC13) 6 3.63 (s, 3H, 0CH3), 7.10-7.36 (m, 4H, ArH), 7.38 (br. s, 2H, NH, NH ), 
8.5 1 (s, 1 H, NH). Anal. Calcd for (C9HI0C1N3O2) C,H,N. 
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Method B. Calcium cyanamide (4.7 g, 58.7 mmol) was dissolved in H 2 0  (10 mL) and the 
solution was added to methyl chloroformate (5.04 g, 53.3 mmol) in a dropwise manner. 
The reaction mixture was allowed to stir for 20 min at 40-45 "C. The precipitate was 
removed by filtration and 3-chloroaniline hydrochloride (115) (4.38 g, 26.7 mmol) was 
added to the filtrate. Concentrated HC1 was added to the reaction mixture to obtain a pH of 
3 and the mixture was heated at reflux for 30 min. The solvent was decanted off and the 
solid was recrystallized from H 2 0  and EtOH to give 113 (0.19 g, 3%) as a white powder: 
mp 159-160 "C; 'H NMR (DMSO-d6) 6 3.78 (s, 3H, CH3), 7.28-7.47 (m, 4H, ArH), 7.52 
(br s, 2H, NH, NH), 8.81 (s, lH, NH). Anal. Calcd for (C9HloC1N302 -1.5HCl -0.25H20) 
C,H,N. 
2-Amino-5-chloro-3,4-dihydroquinazoline Hydrobromide (114). Compound 114 was 
prepared according to a literature procedure.'07 Cyanogen bromide (0.63 mL, 1.87 mmol) 
was added to a solution of 122 (0.25 g, 1.57 rnmol) in absolute EtOH (8 mL). The reaction 
mixture was allowed to stir at room temperature for 1 h and heated at reflux for 5 h. The 
solvent was removed under reduced pressure and H 2 0  (10 mL) was added to the resulting 
residue. The suspension was extracted with CHC13 (3 x 10 mL) and the combined CHC13 
portion was washed with brine (15 mL). The extract was dried with Na2S04 and the 
solvent was removed under reduced pressure. The product was recrystallized from 
absolute EtOH to give 114 (free base; 0.25 g, 88%) as a powder: mp 234-235 "C (litIo7 mp 
221-223 "C); 'H NMR (DMSO-d6) 6 4.37 (s, 2H, CH2N), 6.5-7.0 (m, 3H, ArH). 
Compound 114 (free base) was dissolved in Et20 and the solution was saturated with HBr 
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gas. The precipitate was recrystallized from absolute EtOH to give 114 (0.07 g, 25%) as a 
yellow powder: mp 234-235 OC (lit'07mp 241-243 OC); 'H NMR (DMSO-d6) 6 4.5 (s, 2H, 
CH2N), 6.95-7.32 (m, 3H, 3 ArH), 7.60 (br. s, 2H, NH2), 8.33 (br. s, lH, NH), 10.66 (br. s, 
Dimethyl N,N'-(3-chlorophenyl)guanidinedicarboxylate (116). Methyl chloroformate 
(0.17 mL, 2.15 mmol) in dry THF (2 mL) was added in a dropwise manner to a solution of 
(3-chloropheny1)guanidine (21) free base (0.50 g, 2.15 mmol) and Et3N (0.60 mL, 4.30 
mmol) in dry THF (100 mL) at 0 OC under an N2 atmosphere. The reaction mixture was 
allowed to stir at 0 OC for 30 min and then at room temperature for 16 h. The white 
precipitate was removed by filtration and the solvent was removed under reduced pressure 
to give a beige solid which was recrystallized from absolute EtOH to give 116 (0.13 g, 
21%) as a white powder: mp 160-161; 'H NMR (CDC13) 6 3.59 (s, 3H, 0CH3), 3.75 (s, 
3H, 0CH3), 7.09-7.38 (m, 4H, ArH), 9.60 (br. s, 2H, NH, NH). Anal. Calcd for 
(C 1 lHl2ClN304) C,H,N- 
2-Chloro-6-nitrobenzylbromide (119). Compound 119 was prepared according to a 
literature procedure.'07 N-Bromosuccinimide (8.54 g, 48 mmol) and benzoyl peroxide 
(0.20 g, 0.80 mmol) were added to a solution of 2-chloro-6-nitrotoluene (118) (8.32 g, 48 
mmol) in CC14 (100 mL). The stirred mixture was heated at reflux for 26 h under a 250- 
Watt light bulb. The precipitate was removed by filtration and the solvent was removed 
under reduced pressure. The resulting solid was purified by column chromatography 
(hexaneIEtOAc, 20: 1). The crude product was recrystallized from absolute EtOH to give 
119 (8.25 g, 70%) as yellow crystals: mp 50-52 OC (lit.'07 mp 50-52 OC). 
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N-(2-Chloro-6-nitrobenzy1)phthalamide (120). Compound 120 was prepared according 
to a literature procedure.107 Potassium phthalamide (7.91 g, 10.3 mmol) was added to a 
stirred solution of 119 (2.35 g, 9.36 mmol) in DMF (20 mL). The exothermic reaction 
mixture was allowed to stir for 2 h and cooled to room temperature. Chloroform (10 mL) 
was added to the mixture which was then poured onto H20/ice (55 mL). More CHCI3 (20 
mL) was added to the cooled mixture. The CHC13 portion was separated and washed with 
0.2 N NaOH (26 mL) and brine (20 mL). The extract was dried (Na2S04) and the solvent 
removed under reduced pressure to give 120 as yellow crystals. Compound 120 was used 
without further purification or characterization in the synthesis of 121 
2-Chloro-6-nitrobenzylamine (121). Compound 121 was prepared according to a 
literature procedure.'07 Compound 120 was dissolved in MeOH (15 rnL) and hydrazine 
hydrate (0.52 g, 10.3 mmol) was added. The stirred mixture was heated at reflux for 1 h. 
Water (10 mL) was added to the suspension and the MeOH was removed under reduced 
pressure. The remaining solution was acidified with concentrated HC1 (1 0 mL) and heated 
at reflux for 1 h. The precipitate was removed by filtration and 3 N NaOH was added to 
the filtrate to obtain a pH of 12. Water (15 mL) was added to the solution and the mixture 
was extracted with Et20 (4 x 50 mL) and the Et20 extract was washed with brine (50 mL). 
The extract was dried with Na2S04. The solvent was evaporated under reduced pressure 
and the crude product was purified using Kugelrohr distillation to give 121 (1.19 g, 68%) 
as a yellow oil. 
2-Amino-6-chlorobenzylamine (122). Compound 122 was prepared according to a 
literature procedure.'07 Compound 121 (0.48 g, 2.57 -01) and Raney Ni (0.71 g) in 
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absolute EtOH (12 mL) were placed in a Pan- hydrogenator (psi = 3.5 atm) for 2 h. The 
Raney Ni was removed by filtration and the solvent was removed under reduced pressure. 
The resulting solid was dissolved in absolute EtOH (5 mL) and HCI gas was bubbled 
through the solution, and it was allowed to stand at 0 OC for 1 h. The precipitate was 
removed by filtration and recrystallized from an isopropanol, MeOH, Et20 mixture to give 
122 HCl (0.42 g, 84%) as a powder: mp >240 "C (lit''' mp 263-265); 'H NMR (DMSO- 
d6) 6 4.13 (s, 2H, CH2), 6.59 (s, IH, NH), 6.99-7.02 (m, 2H, ArH), 7.22-7.28 (m, IH, 
ArH), 8.44 (br. s, IH, NH). Compound 122 HCl was dissolved in H 2 0  and 15% NaOH (2 
mL) was added to obtain a pH of 13. The mixture was extracted with Et20 (3 x 40 mL) 
and the combined Et20 portion was dried with Na2S04. The solvent was removed under 
reduced pressure to give 122 (0.25 g, 61%) as a solid. Compound 122 was used without 
further characterization in the synthesis of 114. 
B. Behavioral studies 
1. Animals 
Male ICR mice (24-288) obtained from Harlan Laboratories (Indianapolis, IN) 
were used throughout the study. Mice were housed in groups of five, with free access to 
food and water. Animals were housed in an Association for Assessment and Accreditation 
of Laboratory Animal Care (MALAC)-approved facility, and the study was approved by 
the Institutional Animal Care and Use Committee of Virginia Commonwealth University. 
Mice were allowed to adapt to the testing environment for at least 2 h prior to any 
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treatment. Animals were weighed on the day of the experiment(s) for the calculation of 
drug dosages. 
2. Drugs 
Clonidine hydrochloride, morphine hydrochloride, tropisetron hydrochloride, and 
yohimbine hydrochloride were purchased from Sigma-Aldrich Chemicals, (Milwaukee, 
WI). Compounds 21,113, and 26 were synthesized as reported above. Compound 29 as its 
HC1 salt was resynthesized as reported previously.30 Imiloxan hydrochloride was obtained 
from Tocris (Ballwin, MO). All drugs were dissolved in physiological saline (0.9% sodium 
chloride) and given in a total volume of 10 mL/1000 g body weight by subcutaneous (s.c.) 
injection to the mice. 
3. Behavioral assays 
a) Hot-plate assay 
The method is a modification of that described by Eddy and ~ e i m b a c h " ~  and 
Atwell and ~ a c o b s o n . ' ~ ~  Mice were placed into a 10-cm-wide glass cylinder on a hot-plate 
(Columbus Hot-Plate Analgesia Meter) and the temperature was maintained at 55.0 "C. A 
control response (6-1 0 s) was determined for each mouse before injection and a test latency 
was determined after drug administration. In order to prevent any paw damage, 30 s was 
used as the cutoff time. The antinociceptive response was calculated as percent maximum 
possible effect (% MPE), where % MPE = [(test-control)/ (cutoff time-control)] x 100. 
Groups of 5 to 26 mice were used for each dose and for each treatment. 
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The protocol for testing the antinociceptive effects of these drugs was as follows: 
15 min prior to S.C. administration of drugs, baseline latency was determined for each 
mouse. Clonidine was administered 20 rnin prior to test. MD-354 (21) was administered 
using various (10 to 90 min) pretreatment intervals. In a combination study of MD-354 
/ 
with clonidine, MD-354 was administered 25 rnin prior to clonidine and 45 rnin before the 
test. Compound 29 was administered 45 min prior to test. In a combination study, 29 with 
clonidine, 29 was administered 25 rnin prior to clonidine and 45 min before the test. 
b) Tail-flick assay 
Antinociception was assessed by the tail-flick method of D'Amour and as 
modified by Dewey et a1.'I4 using a Columbus Tail-Flick Analgesia Meter. A control 
latency (1.7-4.0 s) was determined for each mouse before injection, and a test latency was 
determined after drug administration. A cutoff time of 10 s was used to avoid tissue 
damage. The antinociceptive response was calculated in the same manner as in the hot- 
plate assay. Groups of 5 to 16 mice were used for each dose and each treatment. 
The protocol for testing the antinociceptive effects of these drugs was as follows: 
15 rnin prior to S.C. administration of drugs, baseline latency was determined for each 
mouse. MD-354 (21) was administered 45 min before test. In a combination study using 
MD-354 with morphine, MD-354 was administered 15 min before morphine and 45 rnin 
prior to the test. Compound 29 was administered 45 min before the test. In a combination 
study using 29 with clonidine, 29 was administered 25 min before clonidine and 45 rnin 
before the test. In a combination study using 29 and morphine, 29 was administered 15 
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rnin before morphine and 45 min before the test. Tropisetron was administered 5 min 
before 29 and 30 min prior to clonidine. Imiloxan was administered 10 rnin prior to 29 and 
35 rnin before clonidine. Yohimbine was administered 15 min before 29 and 40 min prior 
to clonidine. Compound 113 was administered by using various (5 to 120 min) 
pretreatment intervals. In combination studies using 113 with clonidine, 113 was 
administered 0 to 100 rnin prior to clonidine and 5 to 120 rnin before the test. Compound 
26 was administered 45 min before the test. In combination studies using 26 and clonidine, 
26 was administered 25 min before clonidine and 45 min prior to the test. 
c) Spontaneous activity 
Mice were placed into individual Tru Scan Infrared Locomotor Activity System 
(Coulbourn Instruments, Allentown, PA) photocell activity cages (40 cm cube) after S.C. 
administration of either 0.9% saline or 29 (0.03 mglkg). Ambulatory movement was 
measured by the number of times the animal interrupted the infrared beams traversing the 
cage for a period of 15 min. Measurements were taken 15, 30, and 45 rnin following drug 
treatment. The analysis was focused only on main measures (three main measures: total 
moves, move time, move distance) of activity to determine whether 29 (n = 6ldose) 
depressed this action relative to saline (n = 6) control or whether 29 + clonidine (n = 
6ldose) potentiated the depressed action relative to clonidine (n = 6). The pretreatment 
time for clonidine was 5 min before the test. 
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d) Statistical analysis 
Data were analyzed statistically by an analysis of variance (ANOVA) followed by 
the Newman-Keuls test for multiple post hoc comparison test. The null hypothesis was 
rejected at the 0.05 level. For the time-course studies, each animal was used once. Data 
were analyzed by one-way or a two-factor ANOVA as applicable. ED50 values with 95% 
CL for behavioral data were calculated by unweighted least-square linear regression as 
described by Tallarida and ~ u r r a ~ . ' ' ~  
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